https://trial.medpath.com/news/ose-immunotherapeutics-reports-significant-survival-benefit-in-phase-ii-pancreatic-cancer-vaccine-trial 2025-03-12T16:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ose-immunotherapeutics-reports-significant-survival-benefit-in-phase-ii-pancreatic-cancer-vaccine-trial 2025-03-12T16:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/trial-library-and-aon-partner-to-enhance-cancer-clinical-trial-access-with-ai-enabled-matching-technology 2025-03-12T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trial-library-and-aon-partner-to-enhance-cancer-clinical-trial-access-with-ai-enabled-matching-technology 2025-03-12T16:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/science-translational-medicine-validates-efzofitimod-s-novel-mechanism-for-treating-lung-inflammation 2025-03-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/science-translational-medicine-validates-efzofitimod-s-novel-mechanism-for-treating-lung-inflammation 2025-03-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-test-monitoring-pd-l1-expression-shows-promise-for-improving-immunotherapy-outcomes-in-metastatic-breast-cancer 2025-03-12T15:26:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-test-monitoring-pd-l1-expression-shows-promise-for-improving-immunotherapy-outcomes-in-metastatic-breast-cancer 2025-03-12T15:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/mineralys-therapeutics-secures-175-million-in-public-offering-to-advance-aldosterone-inhibitor-for-cardiorenal-diseases 2025-03-12T14:32:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mineralys-therapeutics-secures-175-million-in-public-offering-to-advance-aldosterone-inhibitor-for-cardiorenal-diseases 2025-03-12T14:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/quralis-reports-promising-phase-1-data-for-qrl-101-in-als-and-epilepsy-biomarker-study 2025-03-12T13:34:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quralis-reports-promising-phase-1-data-for-qrl-101-in-als-and-epilepsy-biomarker-study 2025-03-12T13:34:38+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-expands-diabetes-care-portfolio-with-launch-of-empagliflozin-and-fixed-dose-combinations-in-india 2025-03-12T13:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-expands-diabetes-care-portfolio-with-launch-of-empagliflozin-and-fixed-dose-combinations-in-india 2025-03-12T13:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/redhill-biopharma-to-launch-first-ever-clinical-trial-targeting-map-infection-in-crohn-s-disease 2025-03-12T13:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/redhill-biopharma-to-launch-first-ever-clinical-trial-targeting-map-infection-in-crohn-s-disease 2025-03-12T13:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/gates-foundation-funds-likarda-s-novel-antibody-secreting-cell-therapy-for-infectious-diseases 2025-03-12T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gates-foundation-funds-likarda-s-novel-antibody-secreting-cell-therapy-for-infectious-diseases 2025-03-12T12:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/morning-asthma-testing-yields-more-reliable-results-study-reveals-significant-seasonal-variations 2025-03-12T11:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/morning-asthma-testing-yields-more-reliable-results-study-reveals-significant-seasonal-variations 2025-03-12T11:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/celltrion-s-infliximab-biosimilar-rebranded-as-remdantrytm-in-canada-ensuring-treatment-continuity 2025-03-12T11:50:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celltrion-s-infliximab-biosimilar-rebranded-as-remdantrytm-in-canada-ensuring-treatment-continuity 2025-03-12T11:50:00+00:00 hourly 0.9 https://trial.medpath.com/news/longeveron-s-laromestrocel-shows-promise-in-phase-2a-trial-for-mild-alzheimer-s-disease 2025-03-12T10:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/longeveron-s-laromestrocel-shows-promise-in-phase-2a-trial-for-mild-alzheimer-s-disease 2025-03-12T10:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-initiates-first-clinical-trial-of-nadunolimab-for-aml-and-mds-treatment 2025-03-12T10:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cantargia-initiates-first-clinical-trial-of-nadunolimab-for-aml-and-mds-treatment 2025-03-12T10:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/cognixion-launches-clinical-trial-testing-ai-driven-brain-computer-interface-for-late-stage-als-communication 2025-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cognixion-launches-clinical-trial-testing-ai-driven-brain-computer-interface-for-late-stage-als-communication 2025-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/envoy-medical-secures-10-million-funding-to-advance-pivotal-trial-of-fully-implanted-cochlear-implant 2025-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/envoy-medical-secures-10-million-funding-to-advance-pivotal-trial-of-fully-implanted-cochlear-implant 2025-03-12T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/australian-man-survives-100-days-with-bivacor-artificial-titanium-heart-in-groundbreaking-trial 2025-03-12T08:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australian-man-survives-100-days-with-bivacor-artificial-titanium-heart-in-groundbreaking-trial 2025-03-12T08:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-achieves-diversity-milestone-in-phase-3-psoriasis-trial-with-zasocitinib 2025-03-12T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-achieves-diversity-milestone-in-phase-3-psoriasis-trial-with-zasocitinib 2025-03-12T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/roche-and-zealand-pharma-forge-5-3-billion-partnership-to-develop-novel-obesity-treatments 2025-03-12T07:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-and-zealand-pharma-forge-5-3-billion-partnership-to-develop-novel-obesity-treatments 2025-03-12T07:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/rion-initiates-phase-1b-trial-of-exosome-therapy-pep-for-knee-osteoarthritis 2025-03-12T07:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rion-initiates-phase-1b-trial-of-exosome-therapy-pep-for-knee-osteoarthritis 2025-03-12T07:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/delhi-high-court-upholds-strict-patent-amendment-rules-in-two-key-pharmaceutical-cases 2025-03-12T06:40:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delhi-high-court-upholds-strict-patent-amendment-rules-in-two-key-pharmaceutical-cases 2025-03-12T06:40:29+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-acquires-2seventy-bio-for-286-million-to-gain-full-control-of-car-t-therapy-abecma 2025-03-12T05:02:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-acquires-2seventy-bio-for-286-million-to-gain-full-control-of-car-t-therapy-abecma 2025-03-12T05:02:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-larger-vial-sizes-of-takeda-s-glassia-for-alpha-1-antitrypsin-deficiency 2025-03-12T04:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-larger-vial-sizes-of-takeda-s-glassia-for-alpha-1-antitrypsin-deficiency 2025-03-12T04:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/north-carolina-teen-makes-history-as-first-to-receive-fda-approved-gene-therapy-for-sickle-cell-disease 2025-03-12T04:31:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/north-carolina-teen-makes-history-as-first-to-receive-fda-approved-gene-therapy-for-sickle-cell-disease 2025-03-12T04:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-and-ono-forge-940-million-deal-for-sapablursen-in-polycythemia-vera-treatment 2025-03-12T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-and-ono-forge-940-million-deal-for-sapablursen-in-polycythemia-vera-treatment 2025-03-12T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/colorado-advances-legislation-to-allow-fda-approved-psilocybin-medications 2025-03-12T01:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorado-advances-legislation-to-allow-fda-approved-psilocybin-medications 2025-03-12T01:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/nice-unable-to-recommend-atezolizumab-for-untreated-nsclc-due-to-lack-of-submission 2025-03-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-unable-to-recommend-atezolizumab-for-untreated-nsclc-due-to-lack-of-submission 2025-03-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/patent-strategies-for-glp-1-receptor-agonists-extending-drug-lifecycles-through-novel-applications 2025-03-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patent-strategies-for-glp-1-receptor-agonists-extending-drug-lifecycles-through-novel-applications 2025-03-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neuroone-accelerates-fda-submission-timeline-for-onerf-trigeminal-nerve-ablation-system 2025-03-11T22:33:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neuroone-accelerates-fda-submission-timeline-for-onerf-trigeminal-nerve-ablation-system 2025-03-11T22:33:40+00:00 hourly 0.9 https://trial.medpath.com/news/ose2101-cancer-vaccine-shows-promising-results-in-phase-2-pancreatic-cancer-trial 2025-03-11T22:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ose2101-cancer-vaccine-shows-promising-results-in-phase-2-pancreatic-cancer-trial 2025-03-11T22:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-advances-once-yearly-lenacapavir-for-hiv-prevention-to-phase-iii-after-promising-phase-i-results 2025-03-11T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-advances-once-yearly-lenacapavir-for-hiv-prevention-to-phase-iii-after-promising-phase-i-results 2025-03-11T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/tempus-ai-acquires-deep-6-ai-to-enhance-clinical-trial-matching-and-patient-care 2025-03-11T22:04:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tempus-ai-acquires-deep-6-ai-to-enhance-clinical-trial-matching-and-patient-care 2025-03-11T22:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/harrow-secures-five-year-supply-agreement-for-triesence-r-and-initiates-development-of-next-generation-version 2025-03-11T19:33:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/harrow-secures-five-year-supply-agreement-for-triesence-r-and-initiates-development-of-next-generation-version 2025-03-11T19:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/cms-grants-adlt-status-to-guardant-health-s-shield-blood-test-for-colorectal-cancer-screening 2025-03-11T19:32:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-grants-adlt-status-to-guardant-health-s-shield-blood-test-for-colorectal-cancer-screening 2025-03-11T19:32:52+00:00 hourly 0.9 https://trial.medpath.com/news/radiosa-trial-shows-adt-addition-to-sbrt-improves-progression-free-survival-in-oligorecurrent-prostate-cancer 2025-03-11T19:32:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/radiosa-trial-shows-adt-addition-to-sbrt-improves-progression-free-survival-in-oligorecurrent-prostate-cancer 2025-03-11T19:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/merck-unveils-1b-vaccine-manufacturing-facility-in-north-carolina 2025-03-11T19:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-unveils-1b-vaccine-manufacturing-facility-in-north-carolina 2025-03-11T19:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/shilpa-medicare-unveils-innovative-hybrid-cdmo-model-at-dcat-2025 2025-03-11T19:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shilpa-medicare-unveils-innovative-hybrid-cdmo-model-at-dcat-2025 2025-03-11T19:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-to-acquire-bioreference-health-s-oncology-testing-assets-in-225-million-deal 2025-03-11T19:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-to-acquire-bioreference-health-s-oncology-testing-assets-in-225-million-deal 2025-03-11T19:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/modus-therapeutics-completes-enrollment-for-phase-i-sevuparin-trial-in-pediatric-severe-malaria 2025-03-11T19:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modus-therapeutics-completes-enrollment-for-phase-i-sevuparin-trial-in-pediatric-severe-malaria 2025-03-11T19:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/centerline-biomedical-receives-fda-510-k-clearance-for-expanded-iops-applications-in-neurovascular-procedures 2025-03-11T17:57:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centerline-biomedical-receives-fda-510-k-clearance-for-expanded-iops-applications-in-neurovascular-procedures 2025-03-11T17:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-scientists-develop-promising-nanovaccine-to-prevent-arterial-plaque-build-up 2025-03-11T17:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-scientists-develop-promising-nanovaccine-to-prevent-arterial-plaque-build-up 2025-03-11T17:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/seismic-therapeutic-advances-novel-igg-protease-s-1117-into-phase-1-clinical-trial-for-autoimmune-diseases 2025-03-11T17:03:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seismic-therapeutic-advances-novel-igg-protease-s-1117-into-phase-1-clinical-trial-for-autoimmune-diseases 2025-03-11T17:03:04+00:00 hourly 0.9 https://trial.medpath.com/news/nasal-septum-cartilage-shows-significant-promise-in-repairing-complex-knee-injuries 2025-03-11T17:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nasal-septum-cartilage-shows-significant-promise-in-repairing-complex-knee-injuries 2025-03-11T17:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/aprea-therapeutics-advances-apr-1051-clinical-trial-with-first-hpv-head-and-neck-cancer-patient-dosed 2025-03-11T17:02:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprea-therapeutics-advances-apr-1051-clinical-trial-with-first-hpv-head-and-neck-cancer-patient-dosed 2025-03-11T17:02:58+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-launches-one-medicine-platform-to-accelerate-drug-development 2025-03-11T17:02:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-launches-one-medicine-platform-to-accelerate-drug-development 2025-03-11T17:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-initiates-phase-3-transcend-trial-of-felzartamab-for-late-antibody-mediated-kidney-transplant-rejection 2025-03-11T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-initiates-phase-3-transcend-trial-of-felzartamab-for-late-antibody-mediated-kidney-transplant-rejection 2025-03-11T16:36:53+00:00 hourly 0.9 https://trial.medpath.com/news/right-brain-bio-partners-with-suven-pharmaceuticals-to-manufacture-disease-modifying-parkinson-s-drug-rb-190 2025-03-11T16:35:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/right-brain-bio-partners-with-suven-pharmaceuticals-to-manufacture-disease-modifying-parkinson-s-drug-rb-190 2025-03-11T16:35:34+00:00 hourly 0.9 https://trial.medpath.com/news/great-southern-copper-reports-high-grade-cu-ag-results-from-mostaza-mine-drilling 2025-03-11T16:35:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/great-southern-copper-reports-high-grade-cu-ag-results-from-mostaza-mine-drilling 2025-03-11T16:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-prostate-iq-trial-launches-to-reduce-hormone-therapy-burden-in-prostate-cancer-patients 2025-03-11T16:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-prostate-iq-trial-launches-to-reduce-hormone-therapy-burden-in-prostate-cancer-patients 2025-03-11T16:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/tuhura-biosciences-appoints-former-j-j-oncology-executive-craig-tendler-to-board-of-directors 2025-03-11T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tuhura-biosciences-appoints-former-j-j-oncology-executive-craig-tendler-to-board-of-directors 2025-03-11T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-breakthrough-israeli-team-eliminates-50-of-head-and-neck-tumors-by-targeting-single-gene 2025-03-11T16:34:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-breakthrough-israeli-team-eliminates-50-of-head-and-neck-tumors-by-targeting-single-gene 2025-03-11T16:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-s-icotrokinra-shows-promising-results-in-ulcerative-colitis-and-psoriasis-trials 2025-03-11T16:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-s-icotrokinra-shows-promising-results-in-ulcerative-colitis-and-psoriasis-trials 2025-03-11T16:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/caredx-expands-allosure-testing-to-pediatric-heart-and-simultaneous-pancreas-kidney-transplant-patients 2025-03-11T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caredx-expands-allosure-testing-to-pediatric-heart-and-simultaneous-pancreas-kidney-transplant-patients 2025-03-11T16:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/3d-printing-revolutionizes-drug-delivery-systems-with-precision-and-personalization 2025-03-11T16:34:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3d-printing-revolutionizes-drug-delivery-systems-with-precision-and-personalization 2025-03-11T16:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/elevatebio-and-aws-partner-to-revolutionize-crispr-gene-editing-through-generative-ai 2025-03-11T16:34:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevatebio-and-aws-partner-to-revolutionize-crispr-gene-editing-through-generative-ai 2025-03-11T16:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/kazakhstan-s-breakthrough-cancer-drug-shows-promise-in-clinical-trials-registration-expected-by-2025 2025-03-11T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazakhstan-s-breakthrough-cancer-drug-shows-promise-in-clinical-trials-registration-expected-by-2025 2025-03-11T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-completes-enrollment-in-phase-3-study-of-imlifidase-for-highly-sensitized-kidney-transplant-patients 2025-03-11T16:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-completes-enrollment-in-phase-3-study-of-imlifidase-for-highly-sensitized-kidney-transplant-patients 2025-03-11T16:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-larger-50mm-magdi-magnet-expanding-gt-metabolic-s-magnetic-surgery-capabilities 2025-03-11T16:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-larger-50mm-magdi-magnet-expanding-gt-metabolic-s-magnetic-surgery-capabilities 2025-03-11T16:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/cdc-plans-major-study-on-vaccine-autism-connection-amid-measles-outbreak 2025-03-11T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdc-plans-major-study-on-vaccine-autism-connection-amid-measles-outbreak 2025-03-11T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-accepts-nda-for-sydnexis-syd-101-first-potential-pharmaceutical-treatment-for-pediatric-myopia 2025-03-11T16:08:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-accepts-nda-for-sydnexis-syd-101-first-potential-pharmaceutical-treatment-for-pediatric-myopia 2025-03-11T16:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/lindus-health-and-sooma-medical-launch-phase-3-trial-for-novel-brain-stimulation-device-to-treat-depression 2025-03-11T16:05:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lindus-health-and-sooma-medical-launch-phase-3-trial-for-novel-brain-stimulation-device-to-treat-depression 2025-03-11T16:05:07+00:00 hourly 0.9 https://trial.medpath.com/news/volition-s-nu-q-r-cancer-test-shows-promise-in-lung-cancer-screening-and-pan-cancer-detection 2025-03-11T16:05:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/volition-s-nu-q-r-cancer-test-shows-promise-in-lung-cancer-screening-and-pan-cancer-detection 2025-03-11T16:05:04+00:00 hourly 0.9 https://trial.medpath.com/news/tenon-medical-secures-3-0-million-through-warrant-transaction-to-advance-si-joint-fusion-technology 2025-03-11T15:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenon-medical-secures-3-0-million-through-warrant-transaction-to-advance-si-joint-fusion-technology 2025-03-11T15:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/olumiant-shows-promising-results-for-adolescents-with-alopecia-areata-in-new-study 2025-03-11T14:01:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olumiant-shows-promising-results-for-adolescents-with-alopecia-areata-in-new-study 2025-03-11T14:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-declines-option-for-genmab-s-hexabody-cd38-despite-promising-clinical-data 2025-03-11T14:01:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-declines-option-for-genmab-s-hexabody-cd38-despite-promising-clinical-data 2025-03-11T14:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/ovid-therapeutics-advances-novel-neurological-drug-pipeline-with-key-clinical-milestones-expected-in-2025-2026 2025-03-11T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ovid-therapeutics-advances-novel-neurological-drug-pipeline-with-key-clinical-milestones-expected-in-2025-2026 2025-03-11T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/non-cystic-fibrosis-bronchiectasis-market-expected-to-reach-usd-7-5-billion-by-2035-driven-by-novel-therapies 2025-03-11T13:31:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-cystic-fibrosis-bronchiectasis-market-expected-to-reach-usd-7-5-billion-by-2035-driven-by-novel-therapies 2025-03-11T13:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-caristo-s-ai-powered-cari-plaque-technology-for-early-heart-attack-prevention 2025-03-11T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-caristo-s-ai-powered-cari-plaque-technology-for-early-heart-attack-prevention 2025-03-11T13:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/adaptive-biotechnologies-enhances-clonoseq-assay-for-dlbcl-minimal-residual-disease-detection-with-7-fold-sensitivity-increase 2025-03-11T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adaptive-biotechnologies-enhances-clonoseq-assay-for-dlbcl-minimal-residual-disease-detection-with-7-fold-sensitivity-increase 2025-03-11T12:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/nih-to-sponsor-phase-1-trial-of-fzata-s-novel-oral-biologic-fz002-for-c-difficile-treatment 2025-03-11T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-to-sponsor-phase-1-trial-of-fzata-s-novel-oral-biologic-fz002-for-c-difficile-treatment 2025-03-11T11:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/neogenomics-expands-northeast-presence-with-strategic-acquisition-of-pathline 2025-03-11T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neogenomics-expands-northeast-presence-with-strategic-acquisition-of-pathline 2025-03-11T10:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/vori-health-secures-53-million-series-b-to-transform-musculoskeletal-care-delivery 2025-03-11T09:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vori-health-secures-53-million-series-b-to-transform-musculoskeletal-care-delivery 2025-03-11T09:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/better-choice-company-expands-healthcare-portfolio-with-acquisition-of-choice-specialty-pharmacy 2025-03-11T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/better-choice-company-expands-healthcare-portfolio-with-acquisition-of-choice-specialty-pharmacy 2025-03-11T09:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/medera-completes-dosing-in-phase-1-2a-gene-therapy-trial-for-heart-failure-with-promising-early-results 2025-03-11T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medera-completes-dosing-in-phase-1-2a-gene-therapy-trial-for-heart-failure-with-promising-early-results 2025-03-11T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-pharmaceuticals-receives-mcdc-grant-to-advance-tnx-801-vaccine-against-smallpox-and-mpox 2025-03-11T08:32:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-receives-mcdc-grant-to-advance-tnx-801-vaccine-against-smallpox-and-mpox 2025-03-11T08:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/navigating-the-orphan-drug-landscape-in-europe-hta-challenges-and-the-rising-role-of-real-world-evidence 2025-03-11T08:01:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navigating-the-orphan-drug-landscape-in-europe-hta-challenges-and-the-rising-role-of-real-world-evidence 2025-03-11T08:01:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-sagimet-s-novel-fasn-inhibitor-tvb-3567-for-acne-treatment 2025-03-11T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-sagimet-s-novel-fasn-inhibitor-tvb-3567-for-acne-treatment 2025-03-11T07:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/knight-therapeutics-to-acquire-paladin-in-120-million-strategic-pharmaceutical-deal 2025-03-11T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/knight-therapeutics-to-acquire-paladin-in-120-million-strategic-pharmaceutical-deal 2025-03-11T06:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/resistance-training-emerges-as-most-effective-exercise-for-insomnia-in-older-adults 2025-03-11T06:34:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/resistance-training-emerges-as-most-effective-exercise-for-insomnia-in-older-adults 2025-03-11T06:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/halia-therapeutics-secures-novo-nordisk-golden-ticket-for-innovative-obesity-and-inflammation-research 2025-03-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halia-therapeutics-secures-novo-nordisk-golden-ticket-for-innovative-obesity-and-inflammation-research 2025-03-11T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/leukocyte-count-emerges-as-predictor-for-long-covid-severity-in-postmenopausal-women 2025-03-11T03:01:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leukocyte-count-emerges-as-predictor-for-long-covid-severity-in-postmenopausal-women 2025-03-11T03:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/tevogen-bio-files-patent-for-novel-t-cell-vaccine-targeting-entire-viral-genomes 2025-03-11T02:01:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tevogen-bio-files-patent-for-novel-t-cell-vaccine-targeting-entire-viral-genomes 2025-03-11T02:01:55+00:00 hourly 0.9 https://trial.medpath.com/news/spineart-s-baguera-r-c-cervical-disc-prosthesis-meets-non-inferiority-thresholds-in-both-1-level-and-2-level-ide-studies 2025-03-11T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spineart-s-baguera-r-c-cervical-disc-prosthesis-meets-non-inferiority-thresholds-in-both-1-level-and-2-level-ide-studies 2025-03-11T02:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/scotland-approves-new-cancer-treatments-for-prostate-and-liver-cancers 2025-03-11T01:32:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scotland-approves-new-cancer-treatments-for-prostate-and-liver-cancers 2025-03-11T01:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitors-reduce-thromboembolic-risk-in-myeloproliferative-neoplasms-through-novel-mechanisms 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitors-reduce-thromboembolic-risk-in-myeloproliferative-neoplasms-through-novel-mechanisms 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pet-radiotracer-68ga-fz-nr-1-successfully-identifies-nectin-4-biomarker-in-triple-negative-breast-cancer-patients 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-pet-radiotracer-68ga-fz-nr-1-successfully-identifies-nectin-4-biomarker-in-triple-negative-breast-cancer-patients 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-s-orforglipron-daily-weight-loss-pill-shows-promise-in-phase-3-trial-for-obesity-and-diabetes 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-s-orforglipron-daily-weight-loss-pill-shows-promise-in-phase-3-trial-for-obesity-and-diabetes 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-ruling-on-immunogen-s-dosing-patent-highlights-challenges-in-pharmaceutical-patent-strategy 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-ruling-on-immunogen-s-dosing-patent-highlights-challenges-in-pharmaceutical-patent-strategy 2025-03-11T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vaccinex-to-delist-from-nasdaq-despite-promising-alzheimer-s-drug-results 2025-03-10T23:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaccinex-to-delist-from-nasdaq-despite-promising-alzheimer-s-drug-results 2025-03-10T23:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-and-pfizer-biontech-locked-in-escalating-mrna-patent-battle-with-billions-at-stake 2025-03-10T23:02:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-and-pfizer-biontech-locked-in-escalating-mrna-patent-battle-with-billions-at-stake 2025-03-10T23:02:14+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-achieves-breakthrough-in-base-editing-for-alpha-1-antitrypsin-deficiency 2025-03-10T22:34:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-achieves-breakthrough-in-base-editing-for-alpha-1-antitrypsin-deficiency 2025-03-10T22:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/noramco-group-invests-25-million-to-establish-sterile-injectable-manufacturing-in-new-jersey 2025-03-10T22:33:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/noramco-group-invests-25-million-to-establish-sterile-injectable-manufacturing-in-new-jersey 2025-03-10T22:33:32+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-completes-enrollment-in-glow2-phase-3-trial-for-diabetic-retinopathy-treatment 2025-03-10T22:02:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kodiak-sciences-completes-enrollment-in-glow2-phase-3-trial-for-diabetic-retinopathy-treatment 2025-03-10T22:02:52+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-secures-500-million-in-public-offering-to-advance-base-editing-pipeline 2025-03-10T20:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-secures-500-million-in-public-offering-to-advance-base-editing-pipeline 2025-03-10T20:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-piasky-becomes-first-subcutaneous-pnh-therapy-approved-in-eu 2025-03-10T20:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-piasky-becomes-first-subcutaneous-pnh-therapy-approved-in-eu 2025-03-10T20:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/on-demand-manufacturing-emerges-as-solution-for-adaptive-clinical-trial-challenges-in-small-pharma 2025-03-10T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/on-demand-manufacturing-emerges-as-solution-for-adaptive-clinical-trial-challenges-in-small-pharma 2025-03-10T20:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/msinsight-secures-eur1-6-million-seed-funding-to-transform-msi-cancer-diagnostics 2025-03-10T19:32:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msinsight-secures-eur1-6-million-seed-funding-to-transform-msi-cancer-diagnostics 2025-03-10T19:32:11+00:00 hourly 0.9 https://trial.medpath.com/news/donanemab-alzheimer-s-drug-shows-promise-but-raises-serious-safety-concerns 2025-03-10T19:06:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/donanemab-alzheimer-s-drug-shows-promise-but-raises-serious-safety-concerns 2025-03-10T19:06:22+00:00 hourly 0.9 https://trial.medpath.com/news/hansoh-pharmaceutical-says-nmpa-granted-drug-registration-approval-of-third-indication 2025-03-10T19:06:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansoh-pharmaceutical-says-nmpa-granted-drug-registration-approval-of-third-indication 2025-03-10T19:06:21+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-blackfinbio-s-gene-therapy-trial-for-rare-hereditary-spastic-paraplegia 2025-03-10T19:05:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-blackfinbio-s-gene-therapy-trial-for-rare-hereditary-spastic-paraplegia 2025-03-10T19:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-combination-shows-promise-against-kras-mutated-lung-cancer-resistance 2025-03-10T19:05:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-drug-combination-shows-promise-against-kras-mutated-lung-cancer-resistance 2025-03-10T19:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/mcmaster-university-launches-phase-2-trial-of-novel-inhaled-covid-19-vaccine 2025-03-10T19:05:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mcmaster-university-launches-phase-2-trial-of-novel-inhaled-covid-19-vaccine 2025-03-10T19:05:10+00:00 hourly 0.9 https://trial.medpath.com/news/ema-urges-sponsors-to-maintain-accurate-ctis-data-for-enhanced-clinical-trial-visibility 2025-03-10T19:05:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-urges-sponsors-to-maintain-accurate-ctis-data-for-enhanced-clinical-trial-visibility 2025-03-10T19:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-bear-implant-approval-for-acl-tears-in-children-and-partial-tears 2025-03-10T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-bear-implant-approval-for-acl-tears-in-children-and-partial-tears 2025-03-10T17:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/agilent-s-pd-l1-ihc-28-8-pharmdx-receives-eu-certification-for-lung-cancer-and-melanoma-diagnostics 2025-03-10T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agilent-s-pd-l1-ihc-28-8-pharmdx-receives-eu-certification-for-lung-cancer-and-melanoma-diagnostics 2025-03-10T17:03:48+00:00 hourly 0.9 https://trial.medpath.com/news/eradivir-launches-phase-2-human-challenge-study-for-novel-influenza-therapeutic-ev25 2025-03-10T16:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eradivir-launches-phase-2-human-challenge-study-for-novel-influenza-therapeutic-ev25 2025-03-10T16:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/lixte-s-cancer-drug-lb-100-metabolism-pathway-discovered-opening-new-biomarker-strategy 2025-03-10T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lixte-s-cancer-drug-lb-100-metabolism-pathway-discovered-opening-new-biomarker-strategy 2025-03-10T16:34:18+00:00 hourly 0.9 https://trial.medpath.com/news/alterome-therapeutics-initiates-phase-1-trial-of-novel-pan-kras-inhibitor-alta3263-for-advanced-solid-tumors 2025-03-10T16:34:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alterome-therapeutics-initiates-phase-1-trial-of-novel-pan-kras-inhibitor-alta3263-for-advanced-solid-tumors 2025-03-10T16:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-wainzua-eplontersen-for-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy 2025-03-10T16:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-approves-wainzua-eplontersen-for-hereditary-transthyretin-mediated-amyloidosis-with-polyneuropathy 2025-03-10T16:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/cingulate-advances-ctx-1301-for-adhd-treatment-with-positive-phase-iii-safety-data-and-upcoming-fda-pre-nda-meeting 2025-03-10T16:06:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cingulate-advances-ctx-1301-for-adhd-treatment-with-positive-phase-iii-safety-data-and-upcoming-fda-pre-nda-meeting 2025-03-10T16:06:18+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-expands-portfolio-with-two-gastrointestinal-drugs-for-chronic-idiopathic-constipation 2025-03-10T16:06:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-biopharma-expands-portfolio-with-two-gastrointestinal-drugs-for-chronic-idiopathic-constipation 2025-03-10T16:06:17+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-to-launch-mounjaro-in-major-emerging-markets-by-2025-as-global-demand-soars 2025-03-10T16:06:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-to-launch-mounjaro-in-major-emerging-markets-by-2025-as-global-demand-soars 2025-03-10T16:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-acquires-2seventy-bio-for-102-million-as-gene-therapy-sector-faces-valuation-challenges 2025-03-10T16:06:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-acquires-2seventy-bio-for-102-million-as-gene-therapy-sector-faces-valuation-challenges 2025-03-10T16:06:03+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-artiva-s-allonk-cell-therapy-for-autoimmune-diseases 2025-03-10T16:05:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-artiva-s-allonk-cell-therapy-for-autoimmune-diseases 2025-03-10T16:05:49+00:00 hourly 0.9 https://trial.medpath.com/news/natera-launches-heroes-trial-to-explore-treatment-de-escalation-in-her2-metastatic-breast-cancer 2025-03-10T16:05:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-launches-heroes-trial-to-explore-treatment-de-escalation-in-her2-metastatic-breast-cancer 2025-03-10T16:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-ide-approval-for-lungpacer-s-aeronova-system-in-stari-phase-2-trial-for-respiratory-failure 2025-03-10T16:05:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-ide-approval-for-lungpacer-s-aeronova-system-in-stari-phase-2-trial-for-respiratory-failure 2025-03-10T16:05:47+00:00 hourly 0.9 https://trial.medpath.com/news/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2024-financial-results 2025-03-10T14:02:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2024-financial-results 2025-03-10T14:02:08+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-s-aro-c3-shows-promising-results-in-iga-nephropathy-trial-with-89-reduction-in-c3-levels 2025-03-10T13:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-s-aro-c3-shows-promising-results-in-iga-nephropathy-trial-with-89-reduction-in-c3-levels 2025-03-10T13:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/immunome-initiates-phase-1-trial-of-ror1-targeted-adc-for-b-cell-lymphomas-and-solid-tumors 2025-03-10T13:34:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunome-initiates-phase-1-trial-of-ror1-targeted-adc-for-b-cell-lymphomas-and-solid-tumors 2025-03-10T13:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/agomab-s-agmb-129-shows-promising-results-in-phase-2a-trial-for-fibrostenosing-crohn-s-disease 2025-03-10T13:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agomab-s-agmb-129-shows-promising-results-in-phase-2a-trial-for-fibrostenosing-crohn-s-disease 2025-03-10T13:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/beckman-coulter-s-dxc-500i-clinical-analyzer-receives-fda-clearance-enhancing-integrated-laboratory-testing-capabilities 2025-03-10T13:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beckman-coulter-s-dxc-500i-clinical-analyzer-receives-fda-clearance-enhancing-integrated-laboratory-testing-capabilities 2025-03-10T13:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/vivus-launches-qsymia-in-uae-marking-first-middle-east-market-for-obesity-treatment 2025-03-10T13:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivus-launches-qsymia-in-uae-marking-first-middle-east-market-for-obesity-treatment 2025-03-10T13:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/glenmark-therapeutics-enters-otc-constipation-market-with-polyethylene-glycol-3350-launch 2025-03-10T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glenmark-therapeutics-enters-otc-constipation-market-with-polyethylene-glycol-3350-launch 2025-03-10T13:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-launches-first-generic-xarelto-in-us-market-despite-ongoing-patent-litigation 2025-03-10T13:32:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-launches-first-generic-xarelto-in-us-market-despite-ongoing-patent-litigation 2025-03-10T13:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/beam-therapeutics-reports-breakthrough-in-alpha-1-antitrypsin-deficiency-treatment-with-beam-302-base-editing-therapy 2025-03-10T11:04:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beam-therapeutics-reports-breakthrough-in-alpha-1-antitrypsin-deficiency-treatment-with-beam-302-base-editing-therapy 2025-03-10T11:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/biovica-expands-oncology-partnership-with-us-biotech-firm-in-sek-2-5m-tka-testing-deal 2025-03-10T10:33:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biovica-expands-oncology-partnership-with-us-biotech-firm-in-sek-2-5m-tka-testing-deal 2025-03-10T10:33:47+00:00 hourly 0.9 https://trial.medpath.com/news/aavantgarde-to-present-promising-gene-therapy-data-for-usher-1b-and-stargardt-disease-at-arvo-2025 2025-03-10T10:32:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aavantgarde-to-present-promising-gene-therapy-data-for-usher-1b-and-stargardt-disease-at-arvo-2025 2025-03-10T10:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/isotopia-launches-isoprotrace-for-prostate-cancer-imaging-in-germany-through-dsd-pharma-partnership 2025-03-10T10:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isotopia-launches-isoprotrace-for-prostate-cancer-imaging-in-germany-through-dsd-pharma-partnership 2025-03-10T10:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/her2dx-r-genomic-assay-transforms-treatment-decisions-in-early-stage-her2-breast-cancer 2025-03-10T10:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/her2dx-r-genomic-assay-transforms-treatment-decisions-in-early-stage-her2-breast-cancer 2025-03-10T10:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/diamyd-medical-secures-additional-funding-for-phase-iii-type-1-diabetes-trial-with-fast-track-designation 2025-03-10T10:32:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diamyd-medical-secures-additional-funding-for-phase-iii-type-1-diabetes-trial-with-fast-track-designation 2025-03-10T10:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/avacta-therapeutics-sells-launch-diagnostics-for-ps12-9m-to-focus-on-cancer-drug-development 2025-03-10T10:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avacta-therapeutics-sells-launch-diagnostics-for-ps12-9m-to-focus-on-cancer-drug-development 2025-03-10T10:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/valo-therapeutics-secures-eur19m-funding-to-advance-novel-cancer-immunotherapy-platform 2025-03-10T10:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valo-therapeutics-secures-eur19m-funding-to-advance-novel-cancer-immunotherapy-platform 2025-03-10T10:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/hikma-pharmaceuticals-prepares-to-launch-generic-versions-of-ozempic-and-wegovy 2025-03-10T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hikma-pharmaceuticals-prepares-to-launch-generic-versions-of-ozempic-and-wegovy 2025-03-10T08:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/onemednet-expands-access-to-regulatory-grade-imaging-data-through-strategic-partnerships 2025-03-10T08:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onemednet-expands-access-to-regulatory-grade-imaging-data-through-strategic-partnerships 2025-03-10T08:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/reshape-lifesciences-diabetes-neuromodulation-device-shows-promise-in-preclinical-studies 2025-03-10T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reshape-lifesciences-diabetes-neuromodulation-device-shows-promise-in-preclinical-studies 2025-03-10T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/tethis-and-sheba-medical-center-partner-on-ai-powered-liquid-biopsy-for-early-rectal-cancer-detection 2025-03-10T07:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tethis-and-sheba-medical-center-partner-on-ai-powered-liquid-biopsy-for-early-rectal-cancer-detection 2025-03-10T07:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-to-acquire-checkpoint-therapeutics-in-355-million-deal-for-novel-skin-cancer-treatment 2025-03-10T07:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-to-acquire-checkpoint-therapeutics-in-355-million-deal-for-novel-skin-cancer-treatment 2025-03-10T07:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-secures-usfda-approval-for-generic-ketoconazole-shampoo 2025-03-10T07:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-secures-usfda-approval-for-generic-ketoconazole-shampoo 2025-03-10T07:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reassesses-keytruda-and-opdivo-labels-based-on-pd-l1-biomarker-data-in-gastric-and-esophageal-cancers 2025-03-10T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reassesses-keytruda-and-opdivo-labels-based-on-pd-l1-biomarker-data-in-gastric-and-esophageal-cancers 2025-03-10T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/doer-biologics-completes-phase-2-enrollment-for-novel-tri-specific-agonist-targeting-severe-hypertriglyceridemia 2025-03-10T07:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doer-biologics-completes-phase-2-enrollment-for-novel-tri-specific-agonist-targeting-severe-hypertriglyceridemia 2025-03-10T07:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/baird-medical-expands-global-footprint-secures-indonesian-approval-for-microwave-ablation-technology 2025-03-10T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baird-medical-expands-global-footprint-secures-indonesian-approval-for-microwave-ablation-technology 2025-03-10T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/indian-pharma-companies-to-launch-generic-empagliflozin-at-90-lower-cost 2025-03-10T04:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/indian-pharma-companies-to-launch-generic-empagliflozin-at-90-lower-cost 2025-03-10T04:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/clearmind-medicine-s-psychedelic-combination-treatment-for-cocaine-addiction-receives-patent-publication-in-south-korea 2025-03-10T04:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clearmind-medicine-s-psychedelic-combination-treatment-for-cocaine-addiction-receives-patent-publication-in-south-korea 2025-03-10T04:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-patient-dosed-in-groundbreaking-circular-rna-trial-for-radiation-induced-dry-mouth 2025-03-10T04:02:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patient-dosed-in-groundbreaking-circular-rna-trial-for-radiation-induced-dry-mouth 2025-03-10T04:02:48+00:00 hourly 0.9 https://trial.medpath.com/news/galway-medtech-symphysis-medical-prepares-for-us-launch-of-innovative-cancer-palliative-care-device 2025-03-10T01:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galway-medtech-symphysis-medical-prepares-for-us-launch-of-innovative-cancer-palliative-care-device 2025-03-10T01:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-advances-antisense-therapy-for-angelman-syndrome-to-phase-3-following-promising-clinical-results 2025-03-09T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-advances-antisense-therapy-for-angelman-syndrome-to-phase-3-following-promising-clinical-results 2025-03-09T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/sprim-global-investments-and-oneim-form-300m-joint-venture-to-accelerate-clinical-trial-financing 2025-03-09T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sprim-global-investments-and-oneim-form-300m-joint-venture-to-accelerate-clinical-trial-financing 2025-03-09T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-testing-shows-promise-as-early-predictor-of-biliary-tract-cancer-recurrence 2025-03-09T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctdna-testing-shows-promise-as-early-predictor-of-biliary-tract-cancer-recurrence 2025-03-09T19:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/innocare-pharma-s-tyk2-inhibitor-icp-488-shows-promising-phase-ii-results-for-psoriasis-treatment 2025-03-09T17:01:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innocare-pharma-s-tyk2-inhibitor-icp-488-shows-promising-phase-ii-results-for-psoriasis-treatment 2025-03-09T17:01:47+00:00 hourly 0.9 https://trial.medpath.com/news/tyk-medicines-ty-9591-shows-superior-efficacy-over-osimertinib-in-treating-brain-metastases-from-egfr-mutated-lung-cancer 2025-03-09T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyk-medicines-ty-9591-shows-superior-efficacy-over-osimertinib-in-treating-brain-metastases-from-egfr-mutated-lung-cancer 2025-03-09T16:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/usfda-issues-warning-to-granules-india-over-critical-manufacturing-violations-at-telangana-facility 2025-03-09T14:32:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usfda-issues-warning-to-granules-india-over-critical-manufacturing-violations-at-telangana-facility 2025-03-09T14:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/integrase-inhibitor-hiv-regimens-linked-to-higher-cardiometabolic-risks-reprieve-study-reveals 2025-03-09T14:01:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrase-inhibitor-hiv-regimens-linked-to-higher-cardiometabolic-risks-reprieve-study-reveals 2025-03-09T14:01:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-warning-letter-to-granules-india-for-gmp-violations-at-telangana-facility 2025-03-09T13:33:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-warning-letter-to-granules-india-for-gmp-violations-at-telangana-facility 2025-03-09T13:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/viiv-healthcare-showcases-long-acting-hiv-innovations-and-pipeline-advances-at-croi-2025 2025-03-09T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viiv-healthcare-showcases-long-acting-hiv-innovations-and-pipeline-advances-at-croi-2025 2025-03-09T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/va-hospital-clinical-trials-suspended-due-to-doge-cuts-creating-healthcare-crisis-for-veterans 2025-03-09T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/va-hospital-clinical-trials-suspended-due-to-doge-cuts-creating-healthcare-crisis-for-veterans 2025-03-09T13:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-vip36-targets-cb1-receptor-for-pain-relief-without-cns-side-effects 2025-03-09T08:01:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-drug-vip36-targets-cb1-receptor-for-pain-relief-without-cns-side-effects 2025-03-09T08:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/delgocitinib-cream-shows-super-response-in-nearly-half-of-chronic-hand-eczema-patients 2025-03-09T07:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delgocitinib-cream-shows-super-response-in-nearly-half-of-chronic-hand-eczema-patients 2025-03-09T07:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/same-day-administration-of-g-csf-after-chemotherapy-shows-promise-in-breast-cancer-treatment 2025-03-09T04:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/same-day-administration-of-g-csf-after-chemotherapy-shows-promise-in-breast-cancer-treatment 2025-03-09T04:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/usc-norris-comprehensive-cancer-center-showcases-expanding-role-of-oncology-pharmacists-in-patient-care-and-research 2025-03-09T03:01:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/usc-norris-comprehensive-cancer-center-showcases-expanding-role-of-oncology-pharmacists-in-patient-care-and-research 2025-03-09T03:01:46+00:00 hourly 0.9 https://trial.medpath.com/news/ruxolitinib-cream-shows-long-term-safety-and-efficacy-in-atopic-dermatitis-management 2025-03-09T02:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ruxolitinib-cream-shows-long-term-safety-and-efficacy-in-atopic-dermatitis-management 2025-03-09T02:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/amaran-biotech-partners-with-nippon-fine-chemical-to-advance-nanoparticle-based-drug-manufacturing 2025-03-09T01:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amaran-biotech-partners-with-nippon-fine-chemical-to-advance-nanoparticle-based-drug-manufacturing 2025-03-09T01:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/sfa-therapeutics-reports-positive-phase-1b-results-for-oral-psoriasis-treatment-sfa-002 2025-03-09T01:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sfa-therapeutics-reports-positive-phase-1b-results-for-oral-psoriasis-treatment-sfa-002 2025-03-09T01:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-sciences-resolves-major-patent-disputes-with-1-25b-settlement-to-viiv-and-agreement-with-us-government 2025-03-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-sciences-resolves-major-patent-disputes-with-1-25b-settlement-to-viiv-and-agreement-with-us-government 2025-03-09T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-deal-landscape-february-march-2025-sees-surge-in-partnerships-across-multiple-therapeutic-areas 2025-03-08T23:31:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-deal-landscape-february-march-2025-sees-surge-in-partnerships-across-multiple-therapeutic-areas 2025-03-08T23:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/baricitinib-shows-promising-hair-regrowth-results-in-adolescents-with-severe-alopecia-areata-in-phase-3-trial 2025-03-08T20:02:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baricitinib-shows-promising-hair-regrowth-results-in-adolescents-with-severe-alopecia-areata-in-phase-3-trial 2025-03-08T20:02:30+00:00 hourly 0.9 https://trial.medpath.com/news/rezivertinib-shows-superior-efficacy-over-gefitinib-in-egfr-mutated-nsclc-phase-iii-trial 2025-03-08T19:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezivertinib-shows-superior-efficacy-over-gefitinib-in-egfr-mutated-nsclc-phase-iii-trial 2025-03-08T19:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/innovo-research-and-eagle-physicians-form-strategic-partnership-to-enhance-clinical-trial-access-in-value-based-care-settings 2025-03-08T19:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/innovo-research-and-eagle-physicians-form-strategic-partnership-to-enhance-clinical-trial-access-in-value-based-care-settings 2025-03-08T19:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/dexcom-receives-fda-warning-letter-for-manufacturing-deficiencies-maintains-2025-outlook 2025-03-08T17:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dexcom-receives-fda-warning-letter-for-manufacturing-deficiencies-maintains-2025-outlook 2025-03-08T17:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/ftc-challenges-627m-gtcr-acquisition-of-surmodics-over-market-concentration-concerns 2025-03-08T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ftc-challenges-627m-gtcr-acquisition-of-surmodics-over-market-concentration-concerns 2025-03-08T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/ruxolitinib-cream-shows-promising-results-in-first-phase-3-trials-for-prurigo-nodularis 2025-03-08T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ruxolitinib-cream-shows-promising-results-in-first-phase-3-trials-for-prurigo-nodularis 2025-03-08T16:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/japanese-intergroup-phase-iii-trial-evaluates-ramucirumab-plus-irinotecan-for-third-line-advanced-gastric-cancer-treatment 2025-03-08T13:33:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japanese-intergroup-phase-iii-trial-evaluates-ramucirumab-plus-irinotecan-for-third-line-advanced-gastric-cancer-treatment 2025-03-08T13:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/androgenetic-alopecia-pipeline-shows-promise-with-over-100-therapies-in-development 2025-03-08T13:32:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/androgenetic-alopecia-pipeline-shows-promise-with-over-100-therapies-in-development 2025-03-08T13:32:06+00:00 hourly 0.9 https://trial.medpath.com/news/rocatinlimab-shows-promising-results-in-phase-3-trial-for-moderate-to-severe-atopic-dermatitis 2025-03-08T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rocatinlimab-shows-promising-results-in-phase-3-trial-for-moderate-to-severe-atopic-dermatitis 2025-03-08T13:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/immunogenesis-initiates-phase-i-ii-trial-of-imgs-101-combination-therapy-for-advanced-solid-tumors 2025-03-08T13:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunogenesis-initiates-phase-i-ii-trial-of-imgs-101-combination-therapy-for-advanced-solid-tumors 2025-03-08T13:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-treatment-approaches-show-promise-in-t-cell-lymphoma-therapy 2025-03-08T10:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-treatment-approaches-show-promise-in-t-cell-lymphoma-therapy 2025-03-08T10:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-challenges-bristol-myers-squibb-patents-for-opdivo-yervoy-combination-therapy-in-patent-review-proceedings 2025-03-08T07:31:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-challenges-bristol-myers-squibb-patents-for-opdivo-yervoy-combination-therapy-in-patent-review-proceedings 2025-03-08T07:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/novel-radiotherapeutic-rhenium-obisbemeda-doubles-survival-time-in-glioblastoma-patients 2025-03-08T07:31:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-radiotherapeutic-rhenium-obisbemeda-doubles-survival-time-in-glioblastoma-patients 2025-03-08T07:31:47+00:00 hourly 0.9 https://trial.medpath.com/news/senate-confirms-dr-marty-makary-as-fda-commissioner-signaling-potential-agency-reforms 2025-03-08T02:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-confirms-dr-marty-makary-as-fda-commissioner-signaling-potential-agency-reforms 2025-03-08T02:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/full-circles-therapeutics-secures-uspto-patent-for-revolutionary-circular-single-stranded-dna-genome-editing-platform 2025-03-08T01:33:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/full-circles-therapeutics-secures-uspto-patent-for-revolutionary-circular-single-stranded-dna-genome-editing-platform 2025-03-08T01:33:19+00:00 hourly 0.9 https://trial.medpath.com/news/bimiralisib-gel-shows-promising-results-in-phase-2-trial-for-actinic-keratosis 2025-03-08T01:32:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bimiralisib-gel-shows-promising-results-in-phase-2-trial-for-actinic-keratosis 2025-03-08T01:32:17+00:00 hourly 0.9 https://trial.medpath.com/news/bimzelx-shows-remarkable-five-year-efficacy-in-moderate-to-severe-plaque-psoriasis 2025-03-08T01:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bimzelx-shows-remarkable-five-year-efficacy-in-moderate-to-severe-plaque-psoriasis 2025-03-08T01:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/argenx-showcases-long-term-efficacy-and-safety-data-for-vyvgart-at-aan-2025-meeting 2025-03-08T01:32:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/argenx-showcases-long-term-efficacy-and-safety-data-for-vyvgart-at-aan-2025-meeting 2025-03-08T01:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-dual-designations-to-neu-001-for-hirschsprung-disease-offering-hope-for-non-surgical-treatment 2025-03-08T01:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-dual-designations-to-neu-001-for-hirschsprung-disease-offering-hope-for-non-surgical-treatment 2025-03-08T01:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-mrank-106-first-in-class-dual-wee1-yes1-kinase-inhibitor-for-advanced-solid-tumors 2025-03-08T01:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-mrank-106-first-in-class-dual-wee1-yes1-kinase-inhibitor-for-advanced-solid-tumors 2025-03-08T01:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/unified-clinical-trial-systems-could-reduce-process-steps-by-60-industry-survey-reveals 2025-03-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unified-clinical-trial-systems-could-reduce-process-steps-by-60-industry-survey-reveals 2025-03-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-vosoritide-treatment-shows-sustained-growth-benefits-in-children-with-achondroplasia 2025-03-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-vosoritide-treatment-shows-sustained-growth-benefits-in-children-with-achondroplasia 2025-03-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/medicus-pharma-raises-11-2-million-to-advance-novel-microneedle-patch-for-basal-cell-carcinoma-treatment 2025-03-07T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicus-pharma-raises-11-2-million-to-advance-novel-microneedle-patch-for-basal-cell-carcinoma-treatment 2025-03-07T22:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/orphalan-makes-history-as-first-european-company-to-enter-china-s-wilson-disease-market-with-ke-pei-ou 2025-03-07T20:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orphalan-makes-history-as-first-european-company-to-enter-china-s-wilson-disease-market-with-ke-pei-ou 2025-03-07T20:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/enveda-secures-150m-series-c-with-sanofi-backing-to-advance-ai-driven-natural-drug-discovery 2025-03-07T19:33:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveda-secures-150m-series-c-with-sanofi-backing-to-advance-ai-driven-natural-drug-discovery 2025-03-07T19:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/mission-barns-secures-fda-approval-for-cultivated-pork-fat-prepares-for-historic-us-market-launch 2025-03-07T19:33:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mission-barns-secures-fda-approval-for-cultivated-pork-fat-prepares-for-historic-us-market-launch 2025-03-07T19:33:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-priority-review-vouchers-face-transparency-challenges-amid-rising-prices 2025-03-07T19:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-priority-review-vouchers-face-transparency-challenges-amid-rising-prices 2025-03-07T19:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-shows-rhenium-186re-obisbemeda-doubles-survival-in-recurrent-glioblastoma-patients 2025-03-07T19:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-shows-rhenium-186re-obisbemeda-doubles-survival-in-recurrent-glioblastoma-patients 2025-03-07T19:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/askbio-advances-phase-1-2-gene-therapy-trial-for-rare-muscular-dystrophy-with-second-cohort-dosing 2025-03-07T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/askbio-advances-phase-1-2-gene-therapy-trial-for-rare-muscular-dystrophy-with-second-cohort-dosing 2025-03-07T19:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/nimbus-therapeutics-names-abbas-kazimi-as-new-ceo-in-planned-leadership-transition 2025-03-07T17:03:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nimbus-therapeutics-names-abbas-kazimi-as-new-ceo-in-planned-leadership-transition 2025-03-07T17:03:08+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacy-led-prior-authorization-model-dramatically-reduces-cancer-treatment-delays 2025-03-07T17:02:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacy-led-prior-authorization-model-dramatically-reduces-cancer-treatment-delays 2025-03-07T17:02:43+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-discontinues-depression-trials-for-aticaprant-after-insufficient-efficacy-results 2025-03-07T16:35:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-discontinues-depression-trials-for-aticaprant-after-insufficient-efficacy-results 2025-03-07T16:35:14+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-zimmer-biomet-s-metal-sensitive-revision-knee-implant-for-patients-with-allergies 2025-03-07T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-zimmer-biomet-s-metal-sensitive-revision-knee-implant-for-patients-with-allergies 2025-03-07T16:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/portland-digital-health-startup-secures-fda-approval-for-novel-parkinson-s-disease-device 2025-03-07T16:34:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/portland-digital-health-startup-secures-fda-approval-for-novel-parkinson-s-disease-device 2025-03-07T16:34:34+00:00 hourly 0.9 https://trial.medpath.com/news/lupin-launches-generic-rivaroxaban-in-us-market-following-fda-approval 2025-03-07T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lupin-launches-generic-rivaroxaban-in-us-market-following-fda-approval 2025-03-07T16:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-upholds-regeneron-s-preliminary-injunction-against-samsung-bioepis-in-eylea-patent-dispute 2025-03-07T16:34:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-upholds-regeneron-s-preliminary-injunction-against-samsung-bioepis-in-eylea-patent-dispute 2025-03-07T16:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/merck-s-enpatoran-shows-promise-for-lupus-rash-in-phase-2-trial-despite-mixed-results 2025-03-07T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-s-enpatoran-shows-promise-for-lupus-rash-in-phase-2-trial-despite-mixed-results 2025-03-07T16:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/sensorion-completes-patient-enrollment-in-phase-2a-trial-of-sens-401-for-cisplatin-induced-hearing-loss-prevention 2025-03-07T16:33:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sensorion-completes-patient-enrollment-in-phase-2a-trial-of-sens-401-for-cisplatin-induced-hearing-loss-prevention 2025-03-07T16:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/alberta-expands-public-access-to-pluvicto-radioligand-therapy-for-advanced-prostate-cancer 2025-03-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alberta-expands-public-access-to-pluvicto-radioligand-therapy-for-advanced-prostate-cancer 2025-03-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-launches-innovation-center-at-harvard-s-enterprise-research-campus-to-advance-cvrm-research-and-ai-applications 2025-03-07T14:02:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-launches-innovation-center-at-harvard-s-enterprise-research-campus-to-advance-cvrm-research-and-ai-applications 2025-03-07T14:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-receives-20-million-from-bristol-myers-squibb-for-neurodegenerative-disease-program-advancement 2025-03-07T13:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-receives-20-million-from-bristol-myers-squibb-for-neurodegenerative-disease-program-advancement 2025-03-07T13:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaceutical-industry-braces-for-236-billion-patent-cliff-by-2030-strategic-responses-from-major-players 2025-03-07T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaceutical-industry-braces-for-236-billion-patent-cliff-by-2030-strategic-responses-from-major-players 2025-03-07T13:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapies-transform-rheumatology-landscape-in-early-2025 2025-03-07T10:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-therapies-transform-rheumatology-landscape-in-early-2025 2025-03-07T10:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-agonists-show-significant-benefits-for-kidney-transplant-recipients-with-type-2-diabetes 2025-03-07T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-agonists-show-significant-benefits-for-kidney-transplant-recipients-with-type-2-diabetes 2025-03-07T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-kgaa-s-lupus-drug-fails-to-meet-primary-endpoint-in-phase-ii-sle-trial 2025-03-07T07:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-kgaa-s-lupus-drug-fails-to-meet-primary-endpoint-in-phase-ii-sle-trial 2025-03-07T07:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-faces-turmoil-leadership-changes-and-operational-disruptions-raise-industry-concerns 2025-03-07T07:32:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-faces-turmoil-leadership-changes-and-operational-disruptions-raise-industry-concerns 2025-03-07T07:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-qiagen-s-qiastat-dx-gastrointestinal-panel-2-mini-b-for-clinical-use 2025-03-07T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-qiagen-s-qiastat-dx-gastrointestinal-panel-2-mini-b-for-clinical-use 2025-03-07T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/over-120-pipeline-therapies-target-acute-myeloid-leukemia-as-research-intensifies 2025-03-07T03:07:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/over-120-pipeline-therapies-target-acute-myeloid-leukemia-as-research-intensifies 2025-03-07T03:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-futurist-culture-of-happiness-and-ai-integration-critical-for-future-medical-success 2025-03-07T02:34:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthcare-futurist-culture-of-happiness-and-ai-integration-critical-for-future-medical-success 2025-03-07T02:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/croi-2025-to-showcase-breakthrough-research-in-hiv-covid-19-and-viral-infections 2025-03-07T02:34:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/croi-2025-to-showcase-breakthrough-research-in-hiv-covid-19-and-viral-infections 2025-03-07T02:34:25+00:00 hourly 0.9 https://trial.medpath.com/news/puma-biotechnology-advances-clinical-development-of-alisertib-in-lung-and-breast-cancer 2025-03-07T02:34:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/puma-biotechnology-advances-clinical-development-of-alisertib-in-lung-and-breast-cancer 2025-03-07T02:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/managing-orphan-drug-supply-chains-strategies-to-minimize-stock-losses-in-european-markets 2025-03-07T02:33:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/managing-orphan-drug-supply-chains-strategies-to-minimize-stock-losses-in-european-markets 2025-03-07T02:33:50+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-affirms-dismissal-of-patent-applicant-s-delayed-appointments-clause-challenge 2025-03-07T02:02:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-affirms-dismissal-of-patent-applicant-s-delayed-appointments-clause-challenge 2025-03-07T02:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/cidara-completes-5000-patient-enrollment-in-phase-2b-universal-flu-prevention-trial-secures-105m-financing 2025-03-07T01:33:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cidara-completes-5000-patient-enrollment-in-phase-2b-universal-flu-prevention-trial-secures-105m-financing 2025-03-07T01:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/probiogen-and-marea-achieve-key-manufacturing-milestone-for-novel-acromegaly-antibody-treatment 2025-03-07T01:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/probiogen-and-marea-achieve-key-manufacturing-milestone-for-novel-acromegaly-antibody-treatment 2025-03-07T01:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/gbm-health-secures-1-5m-grant-to-advance-ai-diagnostics-and-sustainable-biomanufacturing 2025-03-07T01:32:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gbm-health-secures-1-5m-grant-to-advance-ai-diagnostics-and-sustainable-biomanufacturing 2025-03-07T01:32:58+00:00 hourly 0.9 https://trial.medpath.com/news/novel-chemo-immunotherapy-approach-shows-promise-for-advanced-hpv-negative-head-and-neck-cancer 2025-03-07T01:32:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-chemo-immunotherapy-approach-shows-promise-for-advanced-hpv-negative-head-and-neck-cancer 2025-03-07T01:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-compassionate-use-approval-for-novel-reverse-hip-replacement-system-in-spinal-fusion-patient 2025-03-07T01:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-compassionate-use-approval-for-novel-reverse-hip-replacement-system-in-spinal-fusion-patient 2025-03-07T01:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-plans-india-entry-for-ozempic-despite-looming-patent-expiry-as-indian-pharma-giants-prepare-generic-alternatives 2025-03-07T00:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-plans-india-entry-for-ozempic-despite-looming-patent-expiry-as-indian-pharma-giants-prepare-generic-alternatives 2025-03-07T00:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/axplora-expands-adc-manufacturing-capabilities-with-new-payload-facility-in-france 2025-03-07T00:02:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/axplora-expands-adc-manufacturing-capabilities-with-new-payload-facility-in-france 2025-03-07T00:02:27+00:00 hourly 0.9 https://trial.medpath.com/news/digital-twins-transform-rare-disease-drug-development-with-virtual-trials-and-ai-powered-simulations 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-twins-transform-rare-disease-drug-development-with-virtual-trials-and-ai-powered-simulations 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-dermasensor-first-ai-powered-skin-cancer-detection-device-for-primary-care 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-dermasensor-first-ai-powered-skin-cancer-detection-device-for-primary-care 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-3d-bioprinter-developed-to-accelerate-drug-discovery-with-enhanced-human-like-tissue-models 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-3d-bioprinter-developed-to-accelerate-drug-discovery-with-enhanced-human-like-tissue-models 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/alnylam-s-vutrisiran-shows-strong-efficacy-in-attr-cardiomyopathy-setting-stage-for-new-treatment-standard 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alnylam-s-vutrisiran-shows-strong-efficacy-in-attr-cardiomyopathy-setting-stage-for-new-treatment-standard 2025-03-06T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/partner-treatment-halves-bacterial-vaginosis-recurrence-rate-in-landmark-trial 2025-03-06T23:02:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/partner-treatment-halves-bacterial-vaginosis-recurrence-rate-in-landmark-trial 2025-03-06T23:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/first-patients-enrolled-in-novel-gene-therapy-trial-for-high-grade-glioma 2025-03-06T22:35:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patients-enrolled-in-novel-gene-therapy-trial-for-high-grade-glioma 2025-03-06T22:35:31+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-panel-mandates-phase-iii-trial-of-baloxavir-marboxil-in-indian-population 2025-03-06T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-panel-mandates-phase-iii-trial-of-baloxavir-marboxil-in-indian-population 2025-03-06T22:35:13+00:00 hourly 0.9 https://trial.medpath.com/news/tenaya-therapeutics-raises-52-5-million-in-strategic-units-offering-to-advance-cardiac-gene-therapy-pipeline 2025-03-06T22:34:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenaya-therapeutics-raises-52-5-million-in-strategic-units-offering-to-advance-cardiac-gene-therapy-pipeline 2025-03-06T22:34:54+00:00 hourly 0.9 https://trial.medpath.com/news/modern-sports-medicine-wellness-partners-with-neuralcure-ai-to-transform-orthobiologic-treatment-using-ai-powered-diagnostics 2025-03-06T22:34:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modern-sports-medicine-wellness-partners-with-neuralcure-ai-to-transform-orthobiologic-treatment-using-ai-powered-diagnostics 2025-03-06T22:34:36+00:00 hourly 0.9 https://trial.medpath.com/news/nice-to-reassess-ps60000-alzheimer-s-drugs-lecanemab-and-donanemab-after-initial-rejection 2025-03-06T22:34:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-to-reassess-ps60000-alzheimer-s-drugs-lecanemab-and-donanemab-after-initial-rejection 2025-03-06T22:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/stryker-unveils-artix-thrombectomy-system-a-breakthrough-in-arterial-blood-clot-treatment 2025-03-06T22:33:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stryker-unveils-artix-thrombectomy-system-a-breakthrough-in-arterial-blood-clot-treatment 2025-03-06T22:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/astellas-and-yaskawa-electric-form-30m-joint-venture-to-revolutionize-cell-therapy-manufacturing 2025-03-06T22:33:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astellas-and-yaskawa-electric-form-30m-joint-venture-to-revolutionize-cell-therapy-manufacturing 2025-03-06T22:33:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-expands-furoscix-approval-to-include-edema-treatment-in-ckd-patients 2025-03-06T22:33:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-expands-furoscix-approval-to-include-edema-treatment-in-ckd-patients 2025-03-06T22:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/spatial-analysis-reveals-key-microglial-mechanisms-in-amyloid-b-clearance-following-alzheimer-s-immunotherapy 2025-03-06T22:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spatial-analysis-reveals-key-microglial-mechanisms-in-amyloid-b-clearance-following-alzheimer-s-immunotherapy 2025-03-06T22:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/oculis-advances-novel-therapies-for-ophthalmic-diseases-with-promising-pipeline-development 2025-03-06T22:32:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oculis-advances-novel-therapies-for-ophthalmic-diseases-with-promising-pipeline-development 2025-03-06T22:32:12+00:00 hourly 0.9 https://trial.medpath.com/news/mindmed-reports-strong-financial-position-with-273-7m-cash-reserve-extending-operations-through-2027 2025-03-06T21:02:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindmed-reports-strong-financial-position-with-273-7m-cash-reserve-extending-operations-through-2027 2025-03-06T21:02:49+00:00 hourly 0.9 https://trial.medpath.com/news/voquezna-achieves-55-3m-revenue-in-first-full-year-shows-strong-market-growth-with-300000-prescriptions 2025-03-06T21:02:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/voquezna-achieves-55-3m-revenue-in-first-full-year-shows-strong-market-growth-with-300000-prescriptions 2025-03-06T21:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/enveric-biosciences-to-divest-psyai-trademark-focuses-on-novel-neuroplastogen-development 2025-03-06T20:33:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enveric-biosciences-to-divest-psyai-trademark-focuses-on-novel-neuroplastogen-development 2025-03-06T20:33:20+00:00 hourly 0.9 https://trial.medpath.com/news/nice-rejects-nhs-coverage-of-eli-lilly-and-biogen-s-alzheimer-s-drugs-due-to-cost-concerns 2025-03-06T20:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-rejects-nhs-coverage-of-eli-lilly-and-biogen-s-alzheimer-s-drugs-due-to-cost-concerns 2025-03-06T20:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/european-patent-board-revokes-c1-esterase-inhibitor-patent-for-kidney-transplant-rejection-treatment 2025-03-06T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-patent-board-revokes-c1-esterase-inhibitor-patent-for-kidney-transplant-rejection-treatment 2025-03-06T19:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/astrazeneca-india-secures-regulatory-approval-for-novel-hyperkalaemia-treatment-lokelma 2025-03-06T19:34:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/astrazeneca-india-secures-regulatory-approval-for-novel-hyperkalaemia-treatment-lokelma 2025-03-06T19:34:17+00:00 hourly 0.9 https://trial.medpath.com/news/dupilumab-shows-strong-efficacy-in-chronic-spontaneous-urticaria-across-all-bmi-ranges 2025-03-06T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dupilumab-shows-strong-efficacy-in-chronic-spontaneous-urticaria-across-all-bmi-ranges 2025-03-06T19:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clinical-trial-launches-for-revolutionary-3d-printed-airway-device-to-treat-infant-breathing-disorder 2025-03-06T19:33:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clinical-trial-launches-for-revolutionary-3d-printed-airway-device-to-treat-infant-breathing-disorder 2025-03-06T19:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/remibrutinib-shows-promising-long-term-efficacy-in-phase-3-trials-for-chronic-spontaneous-urticaria 2025-03-06T19:33:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remibrutinib-shows-promising-long-term-efficacy-in-phase-3-trials-for-chronic-spontaneous-urticaria 2025-03-06T19:33:15+00:00 hourly 0.9 https://trial.medpath.com/news/beckley-psytech-achieves-full-patient-enrollment-in-phase-iib-trial-for-treatment-resistant-depression 2025-03-06T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beckley-psytech-achieves-full-patient-enrollment-in-phase-iib-trial-for-treatment-resistant-depression 2025-03-06T19:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-patients-receive-groundbreaking-autologous-stem-cell-treatment-for-parkinson-s-disease-in-phase-1-trial 2025-03-06T19:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-patients-receive-groundbreaking-autologous-stem-cell-treatment-for-parkinson-s-disease-in-phase-1-trial 2025-03-06T19:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/mindmed-reports-strong-financial-position-and-progress-in-anxiety-treatment-development 2025-03-06T19:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindmed-reports-strong-financial-position-and-progress-in-anxiety-treatment-development 2025-03-06T19:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/plus-therapeutics-receives-fda-orphan-drug-designation-for-novel-lung-cancer-metastasis-treatment 2025-03-06T17:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/plus-therapeutics-receives-fda-orphan-drug-designation-for-novel-lung-cancer-metastasis-treatment 2025-03-06T17:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/tonix-s-fibromyalgia-treatment-shows-promising-phase-3-results-fda-decision-expected-in-2025 2025-03-06T17:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tonix-s-fibromyalgia-treatment-shows-promising-phase-3-results-fda-decision-expected-in-2025 2025-03-06T17:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-launches-phase-3-trials-for-monthly-obesity-drug-maritide 2025-03-06T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-launches-phase-3-trials-for-monthly-obesity-drug-maritide 2025-03-06T17:09:23+00:00 hourly 0.9 https://trial.medpath.com/news/maryland-senate-weighs-200m-medicaid-coverage-for-glp-1-weight-loss-drugs 2025-03-06T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maryland-senate-weighs-200m-medicaid-coverage-for-glp-1-weight-loss-drugs 2025-03-06T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/eth-zurich-unveils-revolutionary-ai-algorithm-for-structure-based-drug-discovery 2025-03-06T17:08:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eth-zurich-unveils-revolutionary-ai-algorithm-for-structure-based-drug-discovery 2025-03-06T17:08:10+00:00 hourly 0.9 https://trial.medpath.com/news/oragenics-advances-onp-002-to-phase-ii-trial-for-concussion-treatment 2025-03-06T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oragenics-advances-onp-002-to-phase-ii-trial-for-concussion-treatment 2025-03-06T16:36:46+00:00 hourly 0.9 https://trial.medpath.com/news/polish-research-team-secures-eur1-2m-grant-for-novel-alzheimer-s-adc-drug-development 2025-03-06T16:36:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polish-research-team-secures-eur1-2m-grant-for-novel-alzheimer-s-adc-drug-development 2025-03-06T16:36:28+00:00 hourly 0.9 https://trial.medpath.com/news/phantom-neuro-s-neural-interface-platform-receives-dual-fda-fast-track-designations-for-prosthetic-control 2025-03-06T16:36:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phantom-neuro-s-neural-interface-platform-receives-dual-fda-fast-track-designations-for-prosthetic-control 2025-03-06T16:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-biologics-and-civica-partner-to-increase-affordable-insulin-aspart-access-in-us-market 2025-03-06T16:35:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-biologics-and-civica-partner-to-increase-affordable-insulin-aspart-access-in-us-market 2025-03-06T16:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mrna-vaccine-shows-promise-in-phase-3-trials-for-cytomegalovirus-prevention 2025-03-06T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mrna-vaccine-shows-promise-in-phase-3-trials-for-cytomegalovirus-prevention 2025-03-06T16:35:29+00:00 hourly 0.9 https://trial.medpath.com/news/izafe-group-s-dosell-digital-medication-dispenser-expands-across-european-markets-with-9-growth 2025-03-06T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/izafe-group-s-dosell-digital-medication-dispenser-expands-across-european-markets-with-9-growth 2025-03-06T16:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/symbiosis-pharmaceutical-services-achieves-zero-gmp-observations-in-fda-gene-therapy-inspection 2025-03-06T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/symbiosis-pharmaceutical-services-achieves-zero-gmp-observations-in-fda-gene-therapy-inspection 2025-03-06T16:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/scienture-launches-rezenopy-most-potent-naloxone-nasal-spray-for-opioid-overdose-treatment 2025-03-06T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scienture-launches-rezenopy-most-potent-naloxone-nasal-spray-for-opioid-overdose-treatment 2025-03-06T16:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-rhenium-obisbemeda-for-lung-cancer-leptomeningeal-metastases 2025-03-06T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-rhenium-obisbemeda-for-lung-cancer-leptomeningeal-metastases 2025-03-06T16:33:56+00:00 hourly 0.9 https://trial.medpath.com/news/adimune-advances-adi-100-towards-clinical-trials-for-multiple-autoimmune-diseases 2025-03-06T16:33:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adimune-advances-adi-100-towards-clinical-trials-for-multiple-autoimmune-diseases 2025-03-06T16:33:34+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-explores-glp-1-drugs-potential-in-addiction-treatment 2025-03-06T16:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-explores-glp-1-drugs-potential-in-addiction-treatment 2025-03-06T16:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/icosabutate-shows-promising-anti-fibrotic-results-in-phase-2b-mash-trial 2025-03-06T16:32:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icosabutate-shows-promising-anti-fibrotic-results-in-phase-2b-mash-trial 2025-03-06T16:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-project-frontrunner-reshapes-early-phase-oncology-drug-development-strategy 2025-03-06T16:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-project-frontrunner-reshapes-early-phase-oncology-drug-development-strategy 2025-03-06T16:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/lindus-health-and-tiefenbacher-group-launch-virtual-clinical-trial-for-me-cfs-treatment 2025-03-06T16:32:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lindus-health-and-tiefenbacher-group-launch-virtual-clinical-trial-for-me-cfs-treatment 2025-03-06T16:32:19+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-launches-phase-1-trial-of-novel-vmat2-inhibitor-for-neurological-disorders 2025-03-06T14:33:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-launches-phase-1-trial-of-novel-vmat2-inhibitor-for-neurological-disorders 2025-03-06T14:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/alx-oncology-launches-phase-ii-studies-in-breast-and-colorectal-cancer-receives-jefferies-upgrade 2025-03-06T14:32:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alx-oncology-launches-phase-ii-studies-in-breast-and-colorectal-cancer-receives-jefferies-upgrade 2025-03-06T14:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/itm-s-phase-3-radiopharmaceutical-shows-promise-in-neuroendocrine-tumor-treatment 2025-03-06T14:03:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itm-s-phase-3-radiopharmaceutical-shows-promise-in-neuroendocrine-tumor-treatment 2025-03-06T14:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/persica-s-novel-antibiotic-shows-promise-in-lower-back-pain-phase-ib-trial 2025-03-06T14:03:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/persica-s-novel-antibiotic-shows-promise-in-lower-back-pain-phase-ib-trial 2025-03-06T14:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/taiwan-court-ruling-tightens-standards-for-pharmaceutical-patent-term-extensions 2025-03-06T14:02:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiwan-court-ruling-tightens-standards-for-pharmaceutical-patent-term-extensions 2025-03-06T14:02:47+00:00 hourly 0.9 https://trial.medpath.com/news/hutchmed-completes-enrollment-for-phase-ii-registration-trial-of-fanregratinib-in-fgfr2-fusion-cholangiocarcinoma 2025-03-06T13:34:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hutchmed-completes-enrollment-for-phase-ii-registration-trial-of-fanregratinib-in-fgfr2-fusion-cholangiocarcinoma 2025-03-06T13:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-breakthrough-therapy-designation-to-olverembatinib-for-ph-leukemia-treatment 2025-03-06T13:34:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-breakthrough-therapy-designation-to-olverembatinib-for-ph-leukemia-treatment 2025-03-06T13:34:04+00:00 hourly 0.9 https://trial.medpath.com/news/aion-labs-and-biomed-x-launch-ai-initiative-to-revolutionize-multi-target-drug-discovery 2025-03-06T13:33:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aion-labs-and-biomed-x-launch-ai-initiative-to-revolutionize-multi-target-drug-discovery 2025-03-06T13:33:43+00:00 hourly 0.9 https://trial.medpath.com/news/congress-s-failure-to-renew-priority-review-voucher-program-threatens-rare-disease-drug-development 2025-03-06T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/congress-s-failure-to-renew-priority-review-voucher-program-threatens-rare-disease-drug-development 2025-03-06T13:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/isomorphic-labs-secures-600m-to-advance-ai-powered-drug-discovery-platform 2025-03-06T11:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/isomorphic-labs-secures-600m-to-advance-ai-powered-drug-discovery-platform 2025-03-06T11:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-expands-zepbound-access-through-noom-and-teladoc-partnerships 2025-03-06T11:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-expands-zepbound-access-through-noom-and-teladoc-partnerships 2025-03-06T11:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/vaxart-s-oral-norovirus-vaccine-shows-promising-immune-response-in-elderly-phase-1b-trial 2025-03-06T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxart-s-oral-norovirus-vaccine-shows-promising-immune-response-in-elderly-phase-1b-trial 2025-03-06T10:33:48+00:00 hourly 0.9 https://trial.medpath.com/news/ten-adalimumab-biosimilars-now-available-in-us-market-following-latest-fda-approval 2025-03-06T10:32:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ten-adalimumab-biosimilars-now-available-in-us-market-following-latest-fda-approval 2025-03-06T10:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/trestle-bio-and-humacyte-partner-to-develop-bioengineered-kidney-tissues-with-vascular-perfusion 2025-03-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trestle-bio-and-humacyte-partner-to-develop-bioengineered-kidney-tissues-with-vascular-perfusion 2025-03-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tivic-health-advances-personalized-non-invasive-vagus-nerve-stimulation-technology-with-promising-new-data 2025-03-06T07:40:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tivic-health-advances-personalized-non-invasive-vagus-nerve-stimulation-technology-with-promising-new-data 2025-03-06T07:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/act-genomics-partners-with-mprobe-to-launch-integrated-proteogenomics-platform-for-advanced-cancer-care-in-asia 2025-03-06T07:33:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/act-genomics-partners-with-mprobe-to-launch-integrated-proteogenomics-platform-for-advanced-cancer-care-in-asia 2025-03-06T07:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/cerus-secures-ce-mark-for-next-gen-intercept-blood-pathogen-inactivation-system 2025-03-06T07:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cerus-secures-ce-mark-for-next-gen-intercept-blood-pathogen-inactivation-system 2025-03-06T07:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-vanda-s-hetlioz-application-for-insomnia-treatment-due-to-insufficient-trial-data 2025-03-06T07:32:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-vanda-s-hetlioz-application-for-insomnia-treatment-due-to-insufficient-trial-data 2025-03-06T07:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/cstone-advances-cs5001-ror1-adc-to-phase-ib-trial-for-first-line-dlbcl-treatment 2025-03-06T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cstone-advances-cs5001-ror1-adc-to-phase-ib-trial-for-first-line-dlbcl-treatment 2025-03-06T07:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/lifeward-partners-with-corlife-to-expand-workers-compensation-access-to-rewalk-exoskeleton 2025-03-06T07:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifeward-partners-with-corlife-to-expand-workers-compensation-access-to-rewalk-exoskeleton 2025-03-06T07:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/icon-partners-with-mural-health-to-enhance-clinical-trial-patient-experience 2025-03-06T07:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icon-partners-with-mural-health-to-enhance-clinical-trial-patient-experience 2025-03-06T07:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/hanall-s-batoclimab-receives-orphan-drug-designation-in-japan-for-thyroid-eye-disease 2025-03-06T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hanall-s-batoclimab-receives-orphan-drug-designation-in-japan-for-thyroid-eye-disease 2025-03-06T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dermata-completes-patient-visits-in-pivotal-phase-3-xyngari-trial-for-moderate-to-severe-acne 2025-03-06T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dermata-completes-patient-visits-in-pivotal-phase-3-xyngari-trial-for-moderate-to-severe-acne 2025-03-06T06:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/biosimilars-market-shows-mixed-progress-36b-in-savings-despite-adoption-challenges 2025-03-06T04:32:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biosimilars-market-shows-mixed-progress-36b-in-savings-despite-adoption-challenges 2025-03-06T04:32:31+00:00 hourly 0.9 https://trial.medpath.com/news/everest-medicines-initiates-first-in-human-trial-of-personalized-mrna-cancer-vaccine-evm16 2025-03-06T03:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/everest-medicines-initiates-first-in-human-trial-of-personalized-mrna-cancer-vaccine-evm16 2025-03-06T03:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/comparative-oncology-breakthrough-how-pet-dogs-are-advancing-human-cancer-treatment 2025-03-06T03:03:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comparative-oncology-breakthrough-how-pet-dogs-are-advancing-human-cancer-treatment 2025-03-06T03:03:10+00:00 hourly 0.9 https://trial.medpath.com/news/asco-issues-major-updates-to-pleural-mesothelioma-treatment-guidelines-emphasizing-immunotherapy-and-selective-surgery 2025-03-06T03:02:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asco-issues-major-updates-to-pleural-mesothelioma-treatment-guidelines-emphasizing-immunotherapy-and-selective-surgery 2025-03-06T03:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/itf-therapeutics-establishes-new-u-s-hub-for-rare-disease-innovation-in-massachusetts 2025-03-06T03:02:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/itf-therapeutics-establishes-new-u-s-hub-for-rare-disease-innovation-in-massachusetts 2025-03-06T03:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/survey-reveals-critical-gaps-in-chronic-hand-eczema-understanding-and-treatment-options 2025-03-06T03:02:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/survey-reveals-critical-gaps-in-chronic-hand-eczema-understanding-and-treatment-options 2025-03-06T03:02:04+00:00 hourly 0.9 https://trial.medpath.com/news/nih-director-nominee-bhattacharya-faces-senate-scrutiny-over-research-funding-and-covid-19-stance 2025-03-06T02:34:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-director-nominee-bhattacharya-faces-senate-scrutiny-over-research-funding-and-covid-19-stance 2025-03-06T02:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-reports-9-growth-in-2024-driven-by-strong-biosimilar-performance 2025-03-06T02:34:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-reports-9-growth-in-2024-driven-by-strong-biosimilar-performance 2025-03-06T02:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/expanding-glp-1-access-a-collaborative-framework-to-address-cost-and-accessibility-challenges 2025-03-06T02:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expanding-glp-1-access-a-collaborative-framework-to-address-cost-and-accessibility-challenges 2025-03-06T02:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/healthcare-llms-face-critical-equity-challenges-new-guidelines-address-bias-and-access-concerns 2025-03-06T02:33:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/healthcare-llms-face-critical-equity-challenges-new-guidelines-address-bias-and-access-concerns 2025-03-06T02:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/delphia-pioneers-activation-lethality-platform-for-novel-cancer-treatment-approach 2025-03-06T02:33:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/delphia-pioneers-activation-lethality-platform-for-novel-cancer-treatment-approach 2025-03-06T02:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/nyxoah-to-present-innovative-osa-treatment-at-oppenheimer-healthcare-conference 2025-03-06T02:32:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyxoah-to-present-innovative-osa-treatment-at-oppenheimer-healthcare-conference 2025-03-06T02:32:50+00:00 hourly 0.9 https://trial.medpath.com/news/olverembatinib-receives-third-breakthrough-therapy-designation-in-china-for-ph-all-treatment 2025-03-06T01:18:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olverembatinib-receives-third-breakthrough-therapy-designation-in-china-for-ph-all-treatment 2025-03-06T01:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/novo-holdings-and-ta-associates-form-strategic-partnership-to-accelerate-biocomposites-growth-in-infection-management 2025-03-06T01:17:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-holdings-and-ta-associates-form-strategic-partnership-to-accelerate-biocomposites-growth-in-infection-management 2025-03-06T01:17:46+00:00 hourly 0.9 https://trial.medpath.com/news/quantoom-biosciences-and-techinvention-partner-to-advance-rna-vaccine-production-in-india 2025-03-06T01:17:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantoom-biosciences-and-techinvention-partner-to-advance-rna-vaccine-production-in-india 2025-03-06T01:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-enhanced-perceval-plus-surgical-valve-with-lancelot-technology 2025-03-06T01:17:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-enhanced-perceval-plus-surgical-valve-with-lancelot-technology 2025-03-06T01:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/the-evolution-of-clinical-trials-embracing-technology-and-collaboration-in-a-post-pandemic-world 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-evolution-of-clinical-trials-embracing-technology-and-collaboration-in-a-post-pandemic-world 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-supported-mammography-screening-demonstrates-17-6-increase-in-breast-cancer-detection-in-real-world-study 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-supported-mammography-screening-demonstrates-17-6-increase-in-breast-cancer-detection-in-real-world-study 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beckman-coulter-and-rarity-bioscience-partner-to-revolutionize-oncology-research-with-enhanced-flow-cytometry 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beckman-coulter-and-rarity-bioscience-partner-to-revolutionize-oncology-research-with-enhanced-flow-cytometry 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/orphan-drug-market-growth-slowing-but-remains-strategic-priority-for-pharma 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orphan-drug-market-growth-slowing-but-remains-strategic-priority-for-pharma 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bi-764532-t-cell-engager-shows-promise-in-dll3-positive-neuroendocrine-carcinomas-with-29-response-rate 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bi-764532-t-cell-engager-shows-promise-in-dll3-positive-neuroendocrine-carcinomas-with-29-response-rate 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-cabenuva-first-long-acting-injectable-hiv-treatment-replaces-daily-pills 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-cabenuva-first-long-acting-injectable-hiv-treatment-replaces-daily-pills 2025-03-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tenax-therapeutics-secures-25m-private-placement-to-advance-phase-3-cardiopulmonary-trials 2025-03-05T23:44:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenax-therapeutics-secures-25m-private-placement-to-advance-phase-3-cardiopulmonary-trials 2025-03-05T23:44:45+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-surprising-link-between-patent-prosecution-length-and-invalidity-risk 2025-03-05T23:44:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-surprising-link-between-patent-prosecution-length-and-invalidity-risk 2025-03-05T23:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-achieves-long-term-remission-in-autoimmune-diseases-through-complete-b-cell-depletion 2025-03-05T23:09:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-achieves-long-term-remission-in-autoimmune-diseases-through-complete-b-cell-depletion 2025-03-05T23:09:45+00:00 hourly 0.9 https://trial.medpath.com/news/global-ebola-pipeline-expands-with-multiple-promising-therapies-in-development-through-2025 2025-03-05T23:08:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-ebola-pipeline-expands-with-multiple-promising-therapies-in-development-through-2025 2025-03-05T23:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/brukinsa-rchop-combination-shows-promise-in-double-expressor-lymphoma-treatment-with-89-6-response-rate 2025-03-05T22:14:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brukinsa-rchop-combination-shows-promise-in-double-expressor-lymphoma-treatment-with-89-6-response-rate 2025-03-05T22:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/novel-combination-therapy-trial-launches-for-inflammatory-diseases-with-hudsonalpha-s-genomic-support 2025-03-05T22:13:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-combination-therapy-trial-launches-for-inflammatory-diseases-with-hudsonalpha-s-genomic-support 2025-03-05T22:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/ataraxis-ai-secures-20-4m-series-a-to-launch-ai-powered-breast-cancer-diagnostic-platform 2025-03-05T22:13:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ataraxis-ai-secures-20-4m-series-a-to-launch-ai-powered-breast-cancer-diagnostic-platform 2025-03-05T22:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/novel-peptide-brp-shows-promise-as-alternative-to-ozempic-for-weight-loss-with-fewer-side-effects 2025-03-05T22:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-peptide-brp-shows-promise-as-alternative-to-ozempic-for-weight-loss-with-fewer-side-effects 2025-03-05T22:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-racial-disparities-in-diabetic-macular-edema-clinical-trials 2025-03-05T22:12:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-racial-disparities-in-diabetic-macular-edema-clinical-trials 2025-03-05T22:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/keytruda-s-cost-effectiveness-questioned-in-advanced-cervical-cancer-treatment-despite-clinical-benefits 2025-03-05T22:12:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/keytruda-s-cost-effectiveness-questioned-in-advanced-cervical-cancer-treatment-despite-clinical-benefits 2025-03-05T22:12:18+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-pipeline-surges-with-180-companies-advancing-novel-cancer-treatments 2025-03-05T22:11:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-pipeline-surges-with-180-companies-advancing-novel-cancer-treatments 2025-03-05T22:11:53+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-for-nasopharyngeal-cancer-treatment-emerges-with-25-pharmaceutical-companies-developing-novel-therapies 2025-03-05T21:54:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-pipeline-for-nasopharyngeal-cancer-treatment-emerges-with-25-pharmaceutical-companies-developing-novel-therapies 2025-03-05T21:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/cps-technologies-secures-third-u-s-army-sbir-contract-to-develop-advanced-materials-for-military-vehicles 2025-03-05T21:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cps-technologies-secures-third-u-s-army-sbir-contract-to-develop-advanced-materials-for-military-vehicles 2025-03-05T21:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/kkr-and-ajax-health-launch-flowmod-to-develop-novel-heart-failure-treatment-platform 2025-03-05T20:09:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kkr-and-ajax-health-launch-flowmod-to-develop-novel-heart-failure-treatment-platform 2025-03-05T20:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/quebec-leads-canada-in-hiv-prevention-first-to-cover-long-acting-injectable-prep-apretude 2025-03-05T19:38:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quebec-leads-canada-in-hiv-prevention-first-to-cover-long-acting-injectable-prep-apretude 2025-03-05T19:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-acquires-chimerix-strengthening-late-stage-pipeline 2025-03-05T19:38:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-acquires-chimerix-strengthening-late-stage-pipeline 2025-03-05T19:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/gfap-biomarker-analysis-shows-ozanimod-s-impact-on-ms-disease-progression-in-enlighten-trial 2025-03-05T19:10:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gfap-biomarker-analysis-shows-ozanimod-s-impact-on-ms-disease-progression-in-enlighten-trial 2025-03-05T19:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-launches-phase-iii-maritime-trials-for-novel-obesity-drug-maritide 2025-03-05T19:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-launches-phase-iii-maritime-trials-for-novel-obesity-drug-maritide 2025-03-05T19:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-small-molecule-drug-shows-promise-in-treating-inflammatory-bowel-disease 2025-03-05T19:09:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-small-molecule-drug-shows-promise-in-treating-inflammatory-bowel-disease 2025-03-05T19:09:36+00:00 hourly 0.9 https://trial.medpath.com/news/aspirin-shows-promise-in-preventing-cancer-metastasis-by-boosting-immune-response 2025-03-05T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aspirin-shows-promise-in-preventing-cancer-metastasis-by-boosting-immune-response 2025-03-05T19:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/biocon-pharma-secures-fda-approval-for-generic-cancer-and-blood-disorder-treatments 2025-03-05T19:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biocon-pharma-secures-fda-approval-for-generic-cancer-and-blood-disorder-treatments 2025-03-05T19:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/novo-nordisk-launches-home-delivery-service-for-wegovy-at-499-monthly-for-cash-paying-patients 2025-03-05T17:38:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novo-nordisk-launches-home-delivery-service-for-wegovy-at-499-monthly-for-cash-paying-patients 2025-03-05T17:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-biontech-s-malaria-vaccine-trial-on-clinical-hold 2025-03-05T17:38:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-biontech-s-malaria-vaccine-trial-on-clinical-hold 2025-03-05T17:38:03+00:00 hourly 0.9 https://trial.medpath.com/news/patent-dispute-emerges-between-merck-and-halozyme-over-injectable-keytruda-formulation 2025-03-05T17:37:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patent-dispute-emerges-between-merck-and-halozyme-over-injectable-keytruda-formulation 2025-03-05T17:37:43+00:00 hourly 0.9 https://trial.medpath.com/news/tscan-therapeutics-reports-promising-results-in-blood-cancer-trial-with-only-8-relapse-rate 2025-03-05T17:10:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tscan-therapeutics-reports-promising-results-in-blood-cancer-trial-with-only-8-relapse-rate 2025-03-05T17:10:53+00:00 hourly 0.9 https://trial.medpath.com/news/oppenheimer-initiates-coverage-of-abeona-s-pz-cel-for-rare-skin-disease-with-optimistic-outlook 2025-03-05T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oppenheimer-initiates-coverage-of-abeona-s-pz-cel-for-rare-skin-disease-with-optimistic-outlook 2025-03-05T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/calcimedica-secures-32-5m-credit-facility-to-advance-crac-channel-inhibitor-development 2025-03-05T17:09:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/calcimedica-secures-32-5m-credit-facility-to-advance-crac-channel-inhibitor-development 2025-03-05T17:09:15+00:00 hourly 0.9 https://trial.medpath.com/news/fda-endorses-expanded-phase-3-program-for-tenax-s-novel-ph-hfpef-treatment-tnx-103 2025-03-05T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-endorses-expanded-phase-3-program-for-tenax-s-novel-ph-hfpef-treatment-tnx-103 2025-03-05T17:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-shows-ivermectin-mass-drug-administration-falls-short-in-malaria-control-efforts 2025-03-05T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-shows-ivermectin-mass-drug-administration-falls-short-in-malaria-control-efforts 2025-03-05T17:08:24+00:00 hourly 0.9 https://trial.medpath.com/news/novel-senolytic-drug-shows-promise-for-masld-and-liver-cancer-treatment 2025-03-05T16:36:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-senolytic-drug-shows-promise-for-masld-and-liver-cancer-treatment 2025-03-05T16:36:28+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ind-for-bioheng-s-off-the-shelf-car-t-therapy-ctd402-for-t-cell-leukemia-lymphoma 2025-03-05T16:11:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ind-for-bioheng-s-off-the-shelf-car-t-therapy-ctd402-for-t-cell-leukemia-lymphoma 2025-03-05T16:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/trimtech-therapeutics-secures-31m-seed-funding-for-novel-protein-degradation-platform-targeting-neurodegenerative-diseases 2025-03-05T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trimtech-therapeutics-secures-31m-seed-funding-for-novel-protein-degradation-platform-targeting-neurodegenerative-diseases 2025-03-05T16:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/lam561-shows-promising-pfs-data-in-mgmt-methylated-glioblastoma-patients 2025-03-05T16:10:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lam561-shows-promising-pfs-data-in-mgmt-methylated-glioblastoma-patients 2025-03-05T16:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-charts-growth-strategy-amid-patent-cliff-biosimilars-and-therapeutic-innovation-take-center-stage 2025-03-05T16:10:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-charts-growth-strategy-amid-patent-cliff-biosimilars-and-therapeutic-innovation-take-center-stage 2025-03-05T16:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-colorado-cancer-center-partners-with-flatiron-health-to-streamline-clinical-trial-data-management 2025-03-05T16:10:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-colorado-cancer-center-partners-with-flatiron-health-to-streamline-clinical-trial-data-management 2025-03-05T16:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/lisata-and-gatc-health-partner-to-accelerate-drug-development-using-ai-platform 2025-03-05T16:09:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lisata-and-gatc-health-partner-to-accelerate-drug-development-using-ai-platform 2025-03-05T16:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/fda-places-clinical-hold-on-biontech-s-novel-malaria-vaccine-trial 2025-03-05T16:09:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-places-clinical-hold-on-biontech-s-novel-malaria-vaccine-trial 2025-03-05T16:09:24+00:00 hourly 0.9 https://trial.medpath.com/news/lipogems-completes-patient-enrollment-in-pivotal-fda-trial-for-knee-osteoarthritis-treatment 2025-03-05T16:09:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lipogems-completes-patient-enrollment-in-pivotal-fda-trial-for-knee-osteoarthritis-treatment 2025-03-05T16:09:04+00:00 hourly 0.9 https://trial.medpath.com/news/whims-trial-legacy-pioneering-study-reshapes-women-s-health-research-and-alzheimer-s-understanding 2025-03-05T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/whims-trial-legacy-pioneering-study-reshapes-women-s-health-research-and-alzheimer-s-understanding 2025-03-05T16:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/asceneuron-discontinues-phase-i-alzheimer-s-trial-of-tau-targeting-drug-asn90 2025-03-05T16:07:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asceneuron-discontinues-phase-i-alzheimer-s-trial-of-tau-targeting-drug-asn90 2025-03-05T16:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-litfulo-becomes-first-nhs-approved-treatment-for-severe-alopecia-areata 2025-03-05T14:39:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-litfulo-becomes-first-nhs-approved-treatment-for-severe-alopecia-areata 2025-03-05T14:39:27+00:00 hourly 0.9 https://trial.medpath.com/news/roche-s-tiragolumab-combination-shows-inferior-outcomes-in-advanced-nsclc-trial 2025-03-05T14:06:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-s-tiragolumab-combination-shows-inferior-outcomes-in-advanced-nsclc-trial 2025-03-05T14:06:31+00:00 hourly 0.9 https://trial.medpath.com/news/osivax-raises-eur10m-in-series-b-funding-to-advance-broad-spectrum-influenza-vaccine-development 2025-03-05T13:39:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/osivax-raises-eur10m-in-series-b-funding-to-advance-broad-spectrum-influenza-vaccine-development 2025-03-05T13:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-to-acquire-chimerix-for-935m-gaining-novel-brain-tumor-drug-candidate 2025-03-05T13:39:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-to-acquire-chimerix-for-935m-gaining-novel-brain-tumor-drug-candidate 2025-03-05T13:39:12+00:00 hourly 0.9 https://trial.medpath.com/news/pliant-therapeutics-discontinues-phase-2b-trial-in-idiopathic-pulmonary-fibrosis 2025-03-05T13:38:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pliant-therapeutics-discontinues-phase-2b-trial-in-idiopathic-pulmonary-fibrosis 2025-03-05T13:38:57+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-validates-safety-shot-s-breakthrough-alcohol-reduction-supplement-in-peer-reviewed-study 2025-03-05T13:38:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-validates-safety-shot-s-breakthrough-alcohol-reduction-supplement-in-peer-reviewed-study 2025-03-05T13:38:37+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-launches-anvimo-game-changing-cmv-prevention-drug-for-transplant-patients-at-91-lower-cost 2025-03-05T13:12:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-launches-anvimo-game-changing-cmv-prevention-drug-for-transplant-patients-at-91-lower-cost 2025-03-05T13:12:43+00:00 hourly 0.9 https://trial.medpath.com/news/australia-s-tga-denies-second-approval-attempt-for-eisai-s-alzheimer-s-drug-leqembi 2025-03-05T13:12:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-s-tga-denies-second-approval-attempt-for-eisai-s-alzheimer-s-drug-leqembi 2025-03-05T13:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/sanyoubio-launches-comprehensive-suite-of-73-bispecific-antibody-reference-products-to-accelerate-drug-development 2025-03-05T13:12:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanyoubio-launches-comprehensive-suite-of-73-bispecific-antibody-reference-products-to-accelerate-drug-development 2025-03-05T13:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-develops-novel-ai-designed-cdk12-13-inhibitors-for-treatment-resistant-cancers 2025-03-05T13:11:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-develops-novel-ai-designed-cdk12-13-inhibitors-for-treatment-resistant-cancers 2025-03-05T13:11:43+00:00 hourly 0.9 https://trial.medpath.com/news/enspire-dbs-therapy-expands-pivotal-stroke-recovery-trial-with-second-site-implementation 2025-03-05T13:11:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enspire-dbs-therapy-expands-pivotal-stroke-recovery-trial-with-second-site-implementation 2025-03-05T13:11:19+00:00 hourly 0.9 https://trial.medpath.com/news/ai-revolutionizes-regenerative-medicine-drug-development-accelerating-parkinson-s-treatment-research 2025-03-05T13:10:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-revolutionizes-regenerative-medicine-drug-development-accelerating-parkinson-s-treatment-research 2025-03-05T13:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-car-t-cell-and-transplantation-research-unveiled-at-2025-tandem-meeting 2025-03-05T13:10:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-car-t-cell-and-transplantation-research-unveiled-at-2025-tandem-meeting 2025-03-05T13:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/understanding-prognostic-vs-predictive-biomarkers-key-distinctions-in-cancer-treatment-strategy 2025-03-05T13:09:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/understanding-prognostic-vs-predictive-biomarkers-key-distinctions-in-cancer-treatment-strategy 2025-03-05T13:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/olverembatinib-shows-promise-in-heavily-pretreated-chronic-myeloid-leukemia 2025-03-05T13:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olverembatinib-shows-promise-in-heavily-pretreated-chronic-myeloid-leukemia 2025-03-05T13:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/apogee-s-novel-atopic-dermatitis-drug-apg777-shows-promising-safety-and-extended-half-life-in-phase-1-trial 2025-03-05T11:39:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/apogee-s-novel-atopic-dermatitis-drug-apg777-shows-promising-safety-and-extended-half-life-in-phase-1-trial 2025-03-05T11:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/olympus-introduces-advanced-retentia-hemoclip-for-enhanced-gi-tract-hemostasis-control 2025-03-05T11:07:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olympus-introduces-advanced-retentia-hemoclip-for-enhanced-gi-tract-hemostasis-control 2025-03-05T11:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-first-generic-rivaroxaban-2-5mg-for-cardiovascular-and-peripheral-artery-disease-prevention 2025-03-05T11:07:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-first-generic-rivaroxaban-2-5mg-for-cardiovascular-and-peripheral-artery-disease-prevention 2025-03-05T11:07:22+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-rules-against-teva-s-orange-book-patent-listings-for-proair-hfa-inhaler 2025-03-05T11:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-rules-against-teva-s-orange-book-patent-listings-for-proair-hfa-inhaler 2025-03-05T11:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/beigene-s-tislelizumab-secures-first-line-approval-for-advanced-nsclc-in-china 2025-03-05T11:06:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beigene-s-tislelizumab-secures-first-line-approval-for-advanced-nsclc-in-china 2025-03-05T11:06:47+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funding-critical-for-advancing-cancer-research-and-treatment-innovation 2025-03-05T11:05:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-funding-critical-for-advancing-cancer-research-and-treatment-innovation 2025-03-05T11:05:08+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-reports-100-success-rate-in-corneal-stem-cell-therapy-trial 2025-03-05T11:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mass-general-brigham-reports-100-success-rate-in-corneal-stem-cell-therapy-trial 2025-03-05T11:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-hr-mp-h2-breast-cancers-share-key-features-with-triple-negative-disease-opening-new-treatment-pathways 2025-03-05T11:04:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-hr-mp-h2-breast-cancers-share-key-features-with-triple-negative-disease-opening-new-treatment-pathways 2025-03-05T11:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/chatgpt-shows-potential-in-developing-dietary-plans-for-masld-management-study-finds 2025-03-05T11:03:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chatgpt-shows-potential-in-developing-dietary-plans-for-masld-management-study-finds 2025-03-05T11:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-path-for-nebokitug-in-primary-sclerosing-cholangitis-treatment-following-successful-phase-2-meeting 2025-03-05T11:02:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-path-for-nebokitug-in-primary-sclerosing-cholangitis-treatment-following-successful-phase-2-meeting 2025-03-05T11:02:51+00:00 hourly 0.9 https://trial.medpath.com/news/health-canada-approves-spark-biomedical-s-drug-free-neurostimulation-device-for-opioid-withdrawal 2025-03-05T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-canada-approves-spark-biomedical-s-drug-free-neurostimulation-device-for-opioid-withdrawal 2025-03-05T09:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/rigel-pharmaceuticals-reports-strong-growth-with-tavalisse-and-rezlidhia-in-2024-expands-global-reach 2025-03-05T08:02:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rigel-pharmaceuticals-reports-strong-growth-with-tavalisse-and-rezlidhia-in-2024-expands-global-reach 2025-03-05T08:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-single-irb-mandate-set-to-streamline-clinical-trial-reviews-by-late-2024 2025-03-05T08:01:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-single-irb-mandate-set-to-streamline-clinical-trial-reviews-by-late-2024 2025-03-05T08:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/precise-hl-trial-launches-to-reduce-chemotherapy-in-hodgkin-lymphoma-using-ctdna-testing 2025-03-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precise-hl-trial-launches-to-reduce-chemotherapy-in-hodgkin-lymphoma-using-ctdna-testing 2025-03-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sernova-biotherapeutics-secures-5-million-in-financing-to-advance-type-1-diabetes-functional-cure 2025-03-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sernova-biotherapeutics-secures-5-million-in-financing-to-advance-type-1-diabetes-functional-cure 2025-03-05T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ivosidenib-plus-cpx-351-shows-promise-in-idh1-mutated-aml-and-high-risk-mds-trial 2025-03-05T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ivosidenib-plus-cpx-351-shows-promise-in-idh1-mutated-aml-and-high-risk-mds-trial 2025-03-05T07:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-signals-potential-shift-in-biosimilar-development-requirements-moving-away-from-phase-iii-trials 2025-03-05T07:31:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-signals-potential-shift-in-biosimilar-development-requirements-moving-away-from-phase-iii-trials 2025-03-05T07:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/garuda-therapeutics-names-avanish-vellanki-as-new-ceo-to-advance-off-the-shelf-stem-cell-platform 2025-03-05T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/garuda-therapeutics-names-avanish-vellanki-as-new-ceo-to-advance-off-the-shelf-stem-cell-platform 2025-03-05T05:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/tc-biopharm-to-acquire-ophthalmic-pharmaceutical-company-with-fda-approved-glaucoma-treatment 2025-03-05T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tc-biopharm-to-acquire-ophthalmic-pharmaceutical-company-with-fda-approved-glaucoma-treatment 2025-03-05T05:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/celon-pharma-s-pde10a-inhibitor-shows-significant-promise-in-phase-2-trial-for-parkinson-s-disease-dyskinesia 2025-03-05T04:33:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celon-pharma-s-pde10a-inhibitor-shows-significant-promise-in-phase-2-trial-for-parkinson-s-disease-dyskinesia 2025-03-05T04:33:12+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-epredia-s-e1000-dx-digital-pathology-solution-for-cancer-diagnostics 2025-03-05T04:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-epredia-s-e1000-dx-digital-pathology-solution-for-cancer-diagnostics 2025-03-05T04:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/matica-biotechnology-partners-with-childs-cure-to-develop-gene-therapy-for-rare-genetic-disorders 2025-03-05T04:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/matica-biotechnology-partners-with-childs-cure-to-develop-gene-therapy-for-rare-genetic-disorders 2025-03-05T04:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/wehi-and-moderna-launch-pioneering-mrna-partnership-to-combat-autoimmune-diseases 2025-03-05T04:32:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wehi-and-moderna-launch-pioneering-mrna-partnership-to-combat-autoimmune-diseases 2025-03-05T04:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-artificial-photosynthesis-system-converts-waste-into-pharmaceutical-compounds 2025-03-05T04:32:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-artificial-photosynthesis-system-converts-waste-into-pharmaceutical-compounds 2025-03-05T04:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-and-sato-pharmaceutical-restructure-nailin-antifungal-marketing-partnership-in-japan 2025-03-05T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-and-sato-pharmaceutical-restructure-nailin-antifungal-marketing-partnership-in-japan 2025-03-05T04:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/microbiome-therapeutics-pipeline-expands-with-180-novel-therapies-in-development-across-140-companies 2025-03-05T04:31:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/microbiome-therapeutics-pipeline-expands-with-180-novel-therapies-in-development-across-140-companies 2025-03-05T04:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/pharmamar-advances-lurbi-eadine-development-with-japanese-licensing-talks-and-european-submission-plans 2025-03-05T02:32:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmamar-advances-lurbi-eadine-development-with-japanese-licensing-talks-and-european-submission-plans 2025-03-05T02:32:37+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-cardiovascular-black-box-warning-from-testosterone-products-following-traverse-trial-results 2025-03-05T02:31:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-cardiovascular-black-box-warning-from-testosterone-products-following-traverse-trial-results 2025-03-05T02:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/cantargia-s-can10-shows-promising-phase-1-results-for-hidradenitis-suppurativa-treatment 2025-03-05T01:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cantargia-s-can10-shows-promising-phase-1-results-for-hidradenitis-suppurativa-treatment 2025-03-05T01:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/antihistamine-addition-to-atezolizumab-doubles-survival-rates-in-metastatic-urothelial-cancer 2025-03-05T01:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antihistamine-addition-to-atezolizumab-doubles-survival-rates-in-metastatic-urothelial-cancer 2025-03-05T01:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/oceanagold-advances-wharekirauponga-project-with-fast-track-application-and-high-grade-results 2025-03-05T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oceanagold-advances-wharekirauponga-project-with-fast-track-application-and-high-grade-results 2025-03-05T01:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-updates-testosterone-product-labels-following-traverse-trial-safety-data 2025-03-05T01:31:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-updates-testosterone-product-labels-following-traverse-trial-safety-data 2025-03-05T01:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/fatal-immune-checkpoint-inhibitor-overlap-syndrome-new-case-series-reveals-critical-management-insights 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fatal-immune-checkpoint-inhibitor-overlap-syndrome-new-case-series-reveals-critical-management-insights 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/minoryx-initiates-phase-2a-trial-of-leriglitazone-for-rett-syndrome 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/minoryx-initiates-phase-2a-trial-of-leriglitazone-for-rett-syndrome 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/boehringer-ingelheim-advances-dual-action-obesity-drug-survodutide-to-phase-3-trials 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boehringer-ingelheim-advances-dual-action-obesity-drug-survodutide-to-phase-3-trials 2025-03-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-s-deramiocel-receives-fda-priority-review-for-duchenne-muscular-dystrophy-treatment 2025-03-04T22:33:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-s-deramiocel-receives-fda-priority-review-for-duchenne-muscular-dystrophy-treatment 2025-03-04T22:33:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-fecal-microbiota-pill-enters-clinical-trial-for-advanced-pancreatic-cancer-treatment 2025-03-04T22:32:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-fecal-microbiota-pill-enters-clinical-trial-for-advanced-pancreatic-cancer-treatment 2025-03-04T22:32:42+00:00 hourly 0.9 https://trial.medpath.com/news/nuvation-bio-secures-250m-financing-for-us-launch-of-ros1-inhibitor-taletrectinib 2025-03-04T22:32:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuvation-bio-secures-250m-financing-for-us-launch-of-ros1-inhibitor-taletrectinib 2025-03-04T22:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/cumberland-pharmaceuticals-reports-breakthrough-in-dmd-treatment-and-11-6-q4-revenue-growth 2025-03-04T22:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cumberland-pharmaceuticals-reports-breakthrough-in-dmd-treatment-and-11-6-q4-revenue-growth 2025-03-04T22:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-emollient-plus-formulation-shows-superior-efficacy-in-atopic-dermatitis-treatment 2025-03-04T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-emollient-plus-formulation-shows-superior-efficacy-in-atopic-dermatitis-treatment 2025-03-04T22:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/novel-pipeline-drugs-show-promise-in-treating-severe-hypertriglyceridemia 2025-03-04T20:32:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-pipeline-drugs-show-promise-in-treating-severe-hypertriglyceridemia 2025-03-04T20:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/senores-pharmaceuticals-acquires-14-andas-from-dr-reddy-s-in-421m-market-opportunity-deal 2025-03-04T20:31:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senores-pharmaceuticals-acquires-14-andas-from-dr-reddy-s-in-421m-market-opportunity-deal 2025-03-04T20:31:33+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-reports-universal-patient-response-in-corneal-stem-cell-therapy-trial 2025-03-04T20:00:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mass-general-brigham-reports-universal-patient-response-in-corneal-stem-cell-therapy-trial 2025-03-04T20:00:09+00:00 hourly 0.9 https://trial.medpath.com/news/first-ascent-biomedical-secures-florida-grant-to-expand-ai-driven-cancer-treatment-platform 2025-03-04T19:59:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-ascent-biomedical-secures-florida-grant-to-expand-ai-driven-cancer-treatment-platform 2025-03-04T19:59:28+00:00 hourly 0.9 https://trial.medpath.com/news/ema-s-chmp-issues-new-drug-recommendations-and-marketing-authorization-updates 2025-03-04T19:59:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-s-chmp-issues-new-drug-recommendations-and-marketing-authorization-updates 2025-03-04T19:59:11+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-revolutionizes-clinical-trial-workflows-with-launch-of-site-lab-navigator-e-requisition-platform 2025-03-04T19:58:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-revolutionizes-clinical-trial-workflows-with-launch-of-site-lab-navigator-e-requisition-platform 2025-03-04T19:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/cleveland-clinic-reports-first-successful-tumor-infiltrating-lymphocyte-therapy-in-metastatic-melanoma-patient 2025-03-04T19:58:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cleveland-clinic-reports-first-successful-tumor-infiltrating-lymphocyte-therapy-in-metastatic-melanoma-patient 2025-03-04T19:58:29+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-nih-policy-shifts-spark-new-focus-on-clinical-trial-accessibility-and-technology-solutions 2025-03-04T19:58:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-nih-policy-shifts-spark-new-focus-on-clinical-trial-accessibility-and-technology-solutions 2025-03-04T19:58:13+00:00 hourly 0.9 https://trial.medpath.com/news/seagen-wins-42m-patent-verdict-against-daiichi-sankyo-over-enhertu-breast-cancer-drug 2025-03-04T19:56:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seagen-wins-42m-patent-verdict-against-daiichi-sankyo-over-enhertu-breast-cancer-drug 2025-03-04T19:56:34+00:00 hourly 0.9 https://trial.medpath.com/news/medable-secures-cnil-approval-for-digital-clinical-trial-solutions-in-european-union 2025-03-04T19:55:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medable-secures-cnil-approval-for-digital-clinical-trial-solutions-in-european-union 2025-03-04T19:55:29+00:00 hourly 0.9 https://trial.medpath.com/news/auxora-shows-63-mortality-reduction-in-covid-19-patients-with-acute-kidney-injury 2025-03-04T19:55:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/auxora-shows-63-mortality-reduction-in-covid-19-patients-with-acute-kidney-injury 2025-03-04T19:55:08+00:00 hourly 0.9 https://trial.medpath.com/news/major-pharma-companies-report-promising-phase-3-results-for-chronic-rhinosinusitis-treatment 2025-03-04T19:54:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/major-pharma-companies-report-promising-phase-3-results-for-chronic-rhinosinusitis-treatment 2025-03-04T19:54:51+00:00 hourly 0.9 https://trial.medpath.com/news/masitinib-shows-promise-in-progressive-ms-treatment-leading-neurologist-highlights-novel-mechanism-of-action 2025-03-04T19:54:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/masitinib-shows-promise-in-progressive-ms-treatment-leading-neurologist-highlights-novel-mechanism-of-action 2025-03-04T19:54:30+00:00 hourly 0.9 https://trial.medpath.com/news/ga-depot-shows-promise-in-progressive-ms-with-3-year-stability-in-disability-scores 2025-03-04T19:54:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ga-depot-shows-promise-in-progressive-ms-with-3-year-stability-in-disability-scores 2025-03-04T19:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-discure-s-novel-bioelectronic-treatment-for-degenerative-disc-disease 2025-03-04T19:53:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fast-tracks-discure-s-novel-bioelectronic-treatment-for-degenerative-disc-disease 2025-03-04T19:53:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-pivotal-trial-of-novel-device-for-post-prostatectomy-incontinence-treatment 2025-03-04T19:53:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-pivotal-trial-of-novel-device-for-post-prostatectomy-incontinence-treatment 2025-03-04T19:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/rsv-treatment-landscape-expands-with-new-vaccines-and-clinical-trials-in-2024-2025 2025-03-04T19:53:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rsv-treatment-landscape-expands-with-new-vaccines-and-clinical-trials-in-2024-2025 2025-03-04T19:53:10+00:00 hourly 0.9 https://trial.medpath.com/news/cingulate-s-once-daily-adhd-drug-ctx-1301-shows-promising-safety-profile-in-phase-3-trials 2025-03-04T19:52:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cingulate-s-once-daily-adhd-drug-ctx-1301-shows-promising-safety-profile-in-phase-3-trials 2025-03-04T19:52:43+00:00 hourly 0.9 https://trial.medpath.com/news/biohaven-s-bhv-7000-fails-primary-endpoint-in-pivotal-bipolar-disorder-trial 2025-03-04T19:52:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biohaven-s-bhv-7000-fails-primary-endpoint-in-pivotal-bipolar-disorder-trial 2025-03-04T19:52:22+00:00 hourly 0.9 https://trial.medpath.com/news/novel-dual-drug-combination-shows-promise-in-treating-resistant-acute-myeloid-leukemia 2025-03-04T19:52:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-dual-drug-combination-shows-promise-in-treating-resistant-acute-myeloid-leukemia 2025-03-04T19:52:03+00:00 hourly 0.9 https://trial.medpath.com/news/simbec-orion-and-avance-clinical-form-strategic-global-cro-partnership-to-enhance-clinical-trial-capabilities 2025-03-04T19:51:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simbec-orion-and-avance-clinical-form-strategic-global-cro-partnership-to-enhance-clinical-trial-capabilities 2025-03-04T19:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/lygenesis-s-phase-2a-liver-regeneration-trial-advances-to-higher-dosing-after-safety-milestone 2025-03-04T19:51:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lygenesis-s-phase-2a-liver-regeneration-trial-advances-to-higher-dosing-after-safety-milestone 2025-03-04T19:51:23+00:00 hourly 0.9 https://trial.medpath.com/news/verana-health-expands-site-explorer-tool-to-boost-diversity-in-clinical-trial-recruitment 2025-03-04T19:51:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verana-health-expands-site-explorer-tool-to-boost-diversity-in-clinical-trial-recruitment 2025-03-04T19:51:08+00:00 hourly 0.9 https://trial.medpath.com/news/cadrenal-therapeutics-partners-with-abbott-to-advance-novel-anticoagulant-trial-for-lvad-patients 2025-03-04T19:50:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cadrenal-therapeutics-partners-with-abbott-to-advance-novel-anticoagulant-trial-for-lvad-patients 2025-03-04T19:50:48+00:00 hourly 0.9 https://trial.medpath.com/news/icon-and-mural-health-partner-to-streamline-clinical-trial-participant-experience-with-digital-payment-platform 2025-03-04T19:50:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/icon-and-mural-health-partner-to-streamline-clinical-trial-participant-experience-with-digital-payment-platform 2025-03-04T19:50:30+00:00 hourly 0.9 https://trial.medpath.com/news/allurion-technologies-secures-new-patents-for-next-generation-obesity-treatment-device 2025-03-04T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allurion-technologies-secures-new-patents-for-next-generation-obesity-treatment-device 2025-03-04T16:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/ku-leuven-and-uz-leuven-launch-eur14-million-advanced-therapy-production-facility 2025-03-04T15:07:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ku-leuven-and-uz-leuven-launch-eur14-million-advanced-therapy-production-facility 2025-03-04T15:07:49+00:00 hourly 0.9 https://trial.medpath.com/news/pharmacists-critical-role-in-improving-access-and-affordability-of-breast-cancer-therapies 2025-03-04T14:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmacists-critical-role-in-improving-access-and-affordability-of-breast-cancer-therapies 2025-03-04T14:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/fairjourney-biologics-expands-global-footprint-with-acquisition-of-charles-river-s-superhuman-antibody-platform 2025-03-04T13:38:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fairjourney-biologics-expands-global-footprint-with-acquisition-of-charles-river-s-superhuman-antibody-platform 2025-03-04T13:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-terminates-rova-t-development-after-5-8b-stemcentrx-deal-becomes-major-r-d-setback 2025-03-04T13:38:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-terminates-rova-t-development-after-5-8b-stemcentrx-deal-becomes-major-r-d-setback 2025-03-04T13:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/enhertu-demonstrates-significant-overall-survival-benefit-in-her2-positive-breast-cancer-phase-iii-trial 2025-03-04T13:37:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enhertu-demonstrates-significant-overall-survival-benefit-in-her2-positive-breast-cancer-phase-iii-trial 2025-03-04T13:37:45+00:00 hourly 0.9 https://trial.medpath.com/news/novel-autologous-cell-therapy-shows-92-success-rate-in-treating-limbal-stem-cell-deficiency 2025-03-04T13:37:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-autologous-cell-therapy-shows-92-success-rate-in-treating-limbal-stem-cell-deficiency 2025-03-04T13:37:24+00:00 hourly 0.9 https://trial.medpath.com/news/phenomix-sciences-revolutionizes-obesity-treatment-with-precision-medicine-approach 2025-03-04T13:37:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phenomix-sciences-revolutionizes-obesity-treatment-with-precision-medicine-approach 2025-03-04T13:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-study-endometrial-immune-profiling-boosts-ivf-success-rates-by-40 2025-03-04T13:36:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-study-endometrial-immune-profiling-boosts-ivf-success-rates-by-40 2025-03-04T13:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/verigraft-secures-eur1-2m-grant-to-develop-revolutionary-3d-printed-vascular-grafts 2025-03-04T13:36:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verigraft-secures-eur1-2m-grant-to-develop-revolutionary-3d-printed-vascular-grafts 2025-03-04T13:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/eton-pharmaceuticals-launches-fda-approved-galzin-for-wilson-disease-maintenance-treatment 2025-03-04T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eton-pharmaceuticals-launches-fda-approved-galzin-for-wilson-disease-maintenance-treatment 2025-03-04T13:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/sofinnova-partners-secures-eur1-2-billion-to-fuel-next-wave-of-biotech-innovation 2025-03-04T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sofinnova-partners-secures-eur1-2-billion-to-fuel-next-wave-of-biotech-innovation 2025-03-04T12:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/dmc-approves-dose-escalation-in-spago-nanomedical-s-177lu-sn201-cancer-trial 2025-03-04T11:32:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dmc-approves-dose-escalation-in-spago-nanomedical-s-177lu-sn201-cancer-trial 2025-03-04T11:32:47+00:00 hourly 0.9 https://trial.medpath.com/news/philips-initiates-class-i-recall-of-tack-endovascular-system-due-to-safety-concerns 2025-03-04T10:32:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/philips-initiates-class-i-recall-of-tack-endovascular-system-due-to-safety-concerns 2025-03-04T10:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/milwaukee-va-emerges-as-top-center-for-veteran-cancer-clinical-trials-with-60-enrollment-rate 2025-03-04T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milwaukee-va-emerges-as-top-center-for-veteran-cancer-clinical-trials-with-60-enrollment-rate 2025-03-04T07:32:16+00:00 hourly 0.9 https://trial.medpath.com/news/deepqure-s-novel-extravascular-rdn-device-shows-promise-in-global-hypertension-trials 2025-03-04T07:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deepqure-s-novel-extravascular-rdn-device-shows-promise-in-global-hypertension-trials 2025-03-04T07:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/nih-funding-critical-for-addressing-gaps-in-pediatric-clinical-trials-study-reveals 2025-03-04T07:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-funding-critical-for-addressing-gaps-in-pediatric-clinical-trials-study-reveals 2025-03-04T07:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/cybrexa-s-novel-peptide-drug-conjugates-show-promising-tumor-selective-activity-in-preclinical-studies 2025-03-04T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cybrexa-s-novel-peptide-drug-conjugates-show-promising-tumor-selective-activity-in-preclinical-studies 2025-03-04T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/momentum-biotechnologies-acquires-omicscouts-to-expand-mass-spectrometry-based-drug-discovery-platform 2025-03-04T07:28:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/momentum-biotechnologies-acquires-omicscouts-to-expand-mass-spectrometry-based-drug-discovery-platform 2025-03-04T07:28:07+00:00 hourly 0.9 https://trial.medpath.com/news/bioxcel-therapeutics-secures-14m-through-direct-stock-offering-to-institutional-investors 2025-03-04T05:32:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioxcel-therapeutics-secures-14m-through-direct-stock-offering-to-institutional-investors 2025-03-04T05:32:36+00:00 hourly 0.9 https://trial.medpath.com/news/aura-biosciences-to-present-new-phase-1-data-for-bel-sar-in-bladder-cancer-at-eau-2025 2025-03-04T05:32:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aura-biosciences-to-present-new-phase-1-data-for-bel-sar-in-bladder-cancer-at-eau-2025 2025-03-04T05:32:10+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-expands-hypertension-portfolio-with-540m-acquisition-of-israeli-tech-firm 2025-03-04T05:31:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-expands-hypertension-portfolio-with-540m-acquisition-of-israeli-tech-firm 2025-03-04T05:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/boston-scientific-acquires-sonivie-for-540m-expanding-into-renal-denervation-market 2025-03-04T04:31:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/boston-scientific-acquires-sonivie-for-540m-expanding-into-renal-denervation-market 2025-03-04T04:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ind-for-laekna-s-novel-usp1-inhibitor-lae120-for-advanced-solid-tumors 2025-03-04T04:31:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ind-for-laekna-s-novel-usp1-inhibitor-lae120-for-advanced-solid-tumors 2025-03-04T04:31:32+00:00 hourly 0.9 https://trial.medpath.com/news/ubrigene-biosciences-advances-cell-therapy-development-with-dmf-submission-for-ipsc-reprogramming-kit 2025-03-04T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ubrigene-biosciences-advances-cell-therapy-development-with-dmf-submission-for-ipsc-reprogramming-kit 2025-03-04T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adverum-launches-groundbreaking-phase-3-artemis-trial-for-one-time-gene-therapy-in-wet-amd 2025-03-04T01:32:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adverum-launches-groundbreaking-phase-3-artemis-trial-for-one-time-gene-therapy-in-wet-amd 2025-03-04T01:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/fda-budget-cuts-under-trump-administration-threaten-drug-development-pipeline 2025-03-04T01:31:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-budget-cuts-under-trump-administration-threaten-drug-development-pipeline 2025-03-04T01:31:40+00:00 hourly 0.9 https://trial.medpath.com/news/onward-medical-secures-2-5m-in-grants-to-explore-arc-im-system-for-parkinson-s-disease-symptoms 2025-03-04T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onward-medical-secures-2-5m-in-grants-to-explore-arc-im-system-for-parkinson-s-disease-symptoms 2025-03-04T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/centauri-therapeutics-advances-novel-immunotherapy-against-gram-negative-bacterial-infections-to-clinical-stage 2025-03-04T01:26:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centauri-therapeutics-advances-novel-immunotherapy-against-gram-negative-bacterial-infections-to-clinical-stage 2025-03-04T01:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-leads-60-million-consortium-to-accelerate-uk-biobank-genome-sequencing-for-alzheimer-s-and-parkinson-s-drug-discovery 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-leads-60-million-consortium-to-accelerate-uk-biobank-genome-sequencing-for-alzheimer-s-and-parkinson-s-drug-discovery 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-il-12-delivery-system-shows-promise-for-advanced-ovarian-cancer-treatment 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-il-12-delivery-system-shows-promise-for-advanced-ovarian-cancer-treatment 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-diversifies-portfolio-with-fda-priority-review-for-upadacitinib-as-humira-faces-biosimilar-competition 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-diversifies-portfolio-with-fda-priority-review-for-upadacitinib-as-humira-faces-biosimilar-competition 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-drug-combination-overcomes-resistance-in-braf-mutated-melanoma-prevents-brain-metastasis 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-drug-combination-overcomes-resistance-in-braf-mutated-melanoma-prevents-brain-metastasis 2025-03-04T00:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/acp-711-shows-promising-safety-profile-in-phase-1-multiple-ascending-dose-study-for-essential-tremor 2025-03-03T23:32:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acp-711-shows-promising-safety-profile-in-phase-1-multiple-ascending-dose-study-for-essential-tremor 2025-03-03T23:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/vaxcyte-nears-critical-phase-ii-readout-for-24-valent-pneumococcal-vaccine 2025-03-03T22:33:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaxcyte-nears-critical-phase-ii-readout-for-24-valent-pneumococcal-vaccine 2025-03-03T22:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/malaria-drug-pyronaridine-shows-promise-as-novel-cancer-treatment 2025-03-03T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/malaria-drug-pyronaridine-shows-promise-as-novel-cancer-treatment 2025-03-03T22:32:59+00:00 hourly 0.9 https://trial.medpath.com/news/ema-s-chmp-recommends-four-new-medicines-for-approval-reaffirms-leqembi-decision 2025-03-03T22:32:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-s-chmp-recommends-four-new-medicines-for-approval-reaffirms-leqembi-decision 2025-03-03T22:32:39+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-ani-pharmaceuticals-cortrophin-gel-prefilled-syringe-for-multiple-autoimmune-conditions 2025-03-03T22:32:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-ani-pharmaceuticals-cortrophin-gel-prefilled-syringe-for-multiple-autoimmune-conditions 2025-03-03T22:32:07+00:00 hourly 0.9 https://trial.medpath.com/news/jak-inhibitors-pipeline-expands-with-55-drug-candidates-as-major-pharma-companies-drive-innovation 2025-03-03T22:31:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jak-inhibitors-pipeline-expands-with-55-drug-candidates-as-major-pharma-companies-drive-innovation 2025-03-03T22:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/tenaya-therapeutics-launches-public-offering-to-advance-cardiac-gene-therapy-pipeline 2025-03-03T21:17:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenaya-therapeutics-launches-public-offering-to-advance-cardiac-gene-therapy-pipeline 2025-03-03T21:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-s-essential-tremor-trial-halted-after-disappointing-interim-analysis 2025-03-03T21:01:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-s-essential-tremor-trial-halted-after-disappointing-interim-analysis 2025-03-03T21:01:37+00:00 hourly 0.9 https://trial.medpath.com/news/deucrictibant-shows-promising-long-term-safety-and-efficacy-in-hereditary-angioedema-treatment 2025-03-03T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/deucrictibant-shows-promising-long-term-safety-and-efficacy-in-hereditary-angioedema-treatment 2025-03-03T19:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/berberine-based-drug-htd1801-shows-promising-results-in-type-2-diabetes-phase-2-trial 2025-03-03T19:35:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/berberine-based-drug-htd1801-shows-promising-results-in-type-2-diabetes-phase-2-trial 2025-03-03T19:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/selpercatinib-shows-sustained-long-term-efficacy-in-ret-fusion-positive-nsclc-patients 2025-03-03T19:35:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selpercatinib-shows-sustained-long-term-efficacy-in-ret-fusion-positive-nsclc-patients 2025-03-03T19:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/protagonist-and-takeda-s-rusfertide-shows-positive-phase-3-results-in-polycythemia-vera 2025-03-03T19:35:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/protagonist-and-takeda-s-rusfertide-shows-positive-phase-3-results-in-polycythemia-vera 2025-03-03T19:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/praxis-precision-faces-setback-as-essential-tremor-drug-trial-falls-short-of-expectations 2025-03-03T19:34:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/praxis-precision-faces-setback-as-essential-tremor-drug-trial-falls-short-of-expectations 2025-03-03T19:34:50+00:00 hourly 0.9 https://trial.medpath.com/news/uc-santa-cruz-clinical-lab-receives-clia-certification-for-revolutionary-pediatric-cancer-rna-testing 2025-03-03T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uc-santa-cruz-clinical-lab-receives-clia-certification-for-revolutionary-pediatric-cancer-rna-testing 2025-03-03T19:34:24+00:00 hourly 0.9 https://trial.medpath.com/news/eco-animal-health-submits-first-eu-vaccine-application-for-poultry-mycoplasma-treatment 2025-03-03T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eco-animal-health-submits-first-eu-vaccine-application-for-poultry-mycoplasma-treatment 2025-03-03T19:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-of-220-drugs-advancing-for-gastric-cancer-treatment-led-by-major-pharmaceutical-companies 2025-03-03T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-pipeline-of-220-drugs-advancing-for-gastric-cancer-treatment-led-by-major-pharmaceutical-companies 2025-03-03T19:33:36+00:00 hourly 0.9 https://trial.medpath.com/news/robust-pipeline-for-ewing-sarcoma-treatment-25-companies-advancing-novel-therapies 2025-03-03T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/robust-pipeline-for-ewing-sarcoma-treatment-25-companies-advancing-novel-therapies 2025-03-03T19:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/aion-healthspan-launches-first-human-trial-of-rejuvxl-cell-therapy-for-chronic-kidney-disease 2025-03-03T19:32:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aion-healthspan-launches-first-human-trial-of-rejuvxl-cell-therapy-for-chronic-kidney-disease 2025-03-03T19:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/fresenius-launches-otulfi-new-stelara-biosimilar-in-us-and-european-markets 2025-03-03T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fresenius-launches-otulfi-new-stelara-biosimilar-in-us-and-european-markets 2025-03-03T19:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-genentech-s-tnkase-for-acute-ischemic-stroke-with-simplified-administration 2025-03-03T19:32:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-genentech-s-tnkase-for-acute-ischemic-stroke-with-simplified-administration 2025-03-03T19:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/myosin-therapeutics-secures-3m-in-second-seed-funding-to-advance-brain-cancer-and-addiction-therapies 2025-03-03T19:31:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myosin-therapeutics-secures-3m-in-second-seed-funding-to-advance-brain-cancer-and-addiction-therapies 2025-03-03T19:31:45+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-diagnamed-s-molecular-hydrogen-therapy-for-als 2025-03-03T18:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-diagnamed-s-molecular-hydrogen-therapy-for-als 2025-03-03T18:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/fda-breakthrough-therapy-status-emerges-as-game-changer-for-oncology-drug-development 2025-03-03T17:33:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-breakthrough-therapy-status-emerges-as-game-changer-for-oncology-drug-development 2025-03-03T17:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-biopharma-secures-strong-financial-position-with-266-5m-cash-reserve-following-successful-ipo 2025-03-03T17:32:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrivent-biopharma-secures-strong-financial-position-with-266-5m-cash-reserve-following-successful-ipo 2025-03-03T17:32:13+00:00 hourly 0.9 https://trial.medpath.com/news/essential-tremor-drug-development-faces-setbacks-as-multiple-clinical-trials-report-disappointing-results 2025-03-03T17:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essential-tremor-drug-development-faces-setbacks-as-multiple-clinical-trials-report-disappointing-results 2025-03-03T17:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/california-s-state-branded-insulin-program-faces-significant-delays-no-clear-launch-timeline 2025-03-03T17:31:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/california-s-state-branded-insulin-program-faces-significant-delays-no-clear-launch-timeline 2025-03-03T17:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/genevant-and-arbutus-launch-global-patent-battle-against-moderna-over-lnp-technology-in-covid-19-vaccine 2025-03-03T17:02:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genevant-and-arbutus-launch-global-patent-battle-against-moderna-over-lnp-technology-in-covid-19-vaccine 2025-03-03T17:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/gensaic-and-novo-nordisk-partner-to-develop-novel-precision-therapeutics-platform 2025-03-03T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gensaic-and-novo-nordisk-partner-to-develop-novel-precision-therapeutics-platform 2025-03-03T17:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/elucid-strengthens-leadership-team-to-launch-ai-powered-atherosclerosis-analysis-software-plaqueiq 2025-03-03T17:01:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elucid-strengthens-leadership-team-to-launch-ai-powered-atherosclerosis-analysis-software-plaqueiq 2025-03-03T17:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/inka-health-pioneers-ai-driven-synthetic-patient-models-for-advancing-oncology-research 2025-03-03T16:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inka-health-pioneers-ai-driven-synthetic-patient-models-for-advancing-oncology-research 2025-03-03T16:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/batteryless-neurostimulator-shows-promising-6-month-results-for-overactive-bladder-treatment 2025-03-03T16:39:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/batteryless-neurostimulator-shows-promising-6-month-results-for-overactive-bladder-treatment 2025-03-03T16:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/trilaciclib-shows-strong-myeloprotection-but-mixed-efficacy-results-in-metastatic-colorectal-cancer-trial 2025-03-03T16:39:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trilaciclib-shows-strong-myeloprotection-but-mixed-efficacy-results-in-metastatic-colorectal-cancer-trial 2025-03-03T16:39:30+00:00 hourly 0.9 https://trial.medpath.com/news/fda-concludes-inspection-of-bioxcel-s-tranquility-ii-phase-3-trial-site-with-vai-status 2025-03-03T16:39:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-concludes-inspection-of-bioxcel-s-tranquility-ii-phase-3-trial-site-with-vai-status 2025-03-03T16:39:13+00:00 hourly 0.9